Cancer evidence library
Breast Cancer
A living PubMed evidence library for breast cancer research, treatment, outcomes, risks, and emerging therapies.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 891 non-retracted PubMed-indexed records for Breast Cancer. The structured collection includes 9 guideline or consensus records, 119 evidence syntheses/systematic reviews/meta-analyses, and 89 randomized or phase III studies. 309 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 687 of 891 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2014
2
2017
2
2020
3
2021
12
2022
17
2023
27
2024
45
2025
779
2026
3
2027
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 3.91 95% CI 1.439–10.624 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 11.35 95% CI 3.45–37.345 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.208 95% CI 0.045–0.967 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.676 95% CI 0.506–0.904 | PMID 41658476 |
| Determinants of patient delay and its association with quality of life among young women with breast cancer in China: A cross-sectional study.Asia-Pacific journal of oncology nursing · 2026 | not_reported | Odds Ratio | 0.921 95% CI 0.855–0.993 | PMID 41658476 |
| Evaluating the Feasibility of Breast-Conserving Surgery in Breast Cancer Patients with Suspicious Calcifications After Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 | not_reported | Percentage Comparison | 73.7percent vs 26.3percent p = 0.012 | PMID 41814780 |
| Evaluating the Feasibility of Breast-Conserving Surgery in Breast Cancer Patients with Suspicious Calcifications After Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026 | not_reported | Odds Ratio | 0.26 95% CI 0.08–0.73 | PMID 41814780 |
| Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.Annals of surgical oncology · 2026 | not_reported | Percentage Comparison | 13.6percent vs 9.7percent | PMID 41874876 |
| Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.Annals of surgical oncology · 2026 | not_reported | Percentage Comparison | 15.4percent vs 12.0percent | PMID 41874876 |
| Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.Annals of surgical oncology · 2026 | not_reported | Percentage Comparison | 13.7percent vs 9.7percent | PMID 41874876 |
| Recent Trends in Whole-Breast Irradiation Versus Partial-Breast Irradiation in Ductal Carcinoma in situ with Breast-Conserving Surgery 2011-2021: A National Cancer Database Study.Annals of surgical oncology · 2026 | not_reported | Percentage Comparison | 13.9percent vs 10.7percent | PMID 41874876 |
| A systematic comparison of abbreviated and unenhanced breast MRI protocols in women with mammographically dense breasts compared to full multiparametric breast MR imaging.European journal of radiology · 2026 | not_reported | Odds Ratio | 3.0 | PMID 41967277 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 26.0 | PMID 42067068 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 3.7 p = 0.002 | PMID 42067068 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 3.31 p = 0.002 | PMID 42067068 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 3.67 p = 0.003 | PMID 42067068 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 1.08 p = 0.003 | PMID 42067068 |
| Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial.JAMA surgery · 2026 | not_reported | Odds Ratio | 2.0 | PMID 42090164 |
| Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.Pakistan journal of pharmaceutical sciences · 2026 | recurrence | Odds Ratio | 6.0 P>0.05 | PMID 42262213 |
| Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.The Lancet. Oncology · 2026 | mortality | Hazard Ratio | 0.0 | PMID 42372743 |
| Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.The Lancet. Oncology · 2026 | mortality | Hazard Ratio | 1.0 | PMID 42372743 |
| An exploratory pre-clinical study of the combination of hyperthermia and checkpoint inhibitors.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 | not_reported | Odds Ratio | 1.0 | PMID 42517178 |
| Revolutionizing Precision of Necrosis: Laser Speckle Contrast Imaging versus Indocyanine Green for Breast Flap Viability.Plastic and reconstructive surgery · 2026 | not_reported | Percentage Comparison | 87.1percent vs 81.82percent | PMID 42519935 |
| Revolutionizing Precision of Necrosis: Laser Speckle Contrast Imaging versus Indocyanine Green for Breast Flap Viability.Plastic and reconstructive surgery · 2026 | not_reported | Percentage Comparison | 80.42percent vs 71.6percent | PMID 42519935 |
| Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.Breast (Edinburgh, Scotland) · 2026 | not_reported | Odds Ratio | 2.91 95% CI 2.19–3.87 | PMID 42330687 |
| Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.Breast (Edinburgh, Scotland) · 2026 | not_reported | Odds Ratio | 1.18 | PMID 42330687 |
| Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.Breast (Edinburgh, Scotland) · 2026 | not_reported | Odds Ratio | 1.8 95% CI 1.37–2.36 | PMID 42330687 |
| Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.Breast (Edinburgh, Scotland) · 2026 | not_reported | Odds Ratio | 2.01 95% CI 1.39–2.89 | PMID 42330687 |
| Comparison of Clinicopathological Features and Survival Between Distant Lymph Node Metastasis and Distant Micrometastasis in Breast Cancer.Clinical breast cancer · 2026 | not_reported | Hazard Ratio | 3.82 | PMID 42508205 |
| Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Odds Ratio | 1.03 95% CI 0.96–1.11 p = 0.007 | PMID 42308863 |
| Evaluation of Pharmacokinetics and Safety of Imlunestrant in Participants with Hepatic Impairment.Journal of clinical pharmacology · 2026 | not_reported | Odds Ratio | 400.0 | PMID 42394141 |
| A Prospective Head-to-Head Comparison of HER2-Targeted and 18 F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.Clinical nuclear medicine · 2026 | not_reported | Percentage Comparison | 90.0percent vs 62.0percent P <0.001 | PMID 42377932 |
| Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).International journal of cancer · 2026 | not_reported | Hazard Ratio | 2.48 95% CI 1.82–3.37 | PMID 41968390 |
| Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).International journal of cancer · 2026 | not_reported | Hazard Ratio | 2.38 95% CI 1.74–3.27 | PMID 41968390 |
| Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Odds Ratio | 0.396 | PMID 42341617 |
| Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Odds Ratio | 0.224 | PMID 42341617 |
| Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 | progression-free survival | Percentage Comparison | 23.7percent vs 5.3percent p = 0.01 | PMID 42337391 |
| Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 | progression-free survival | Percentage Comparison | 88.1percent vs 57.9percent p = 0.01 | PMID 42337391 |
| Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 | not_reported | Percentage Comparison | 87.5percent vs 48.0percent | PMID 42337391 |
| Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.Cancer biology & therapy · 2026 | not_reported | Percentage Comparison | 20.8percent vs 4.0percent p = 0.08 | PMID 42337391 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS129
National Natural Science Foundation of China41
NIGMS NIH HHS24
NHLBI NIH HHS21
NIH HHS13
The Region of Västmanland13
NCATS NIH HHS12
National Cancer Institute (NCI)11
View records with declared financial or industry relationships 12
Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
Declaration of interests L.J.v.‘t.V. is a part-time employee and stockholder of Agendia. L.J.E. reported that she is an uncompensated board member of the Quantum Leap Healthcare Collaborative, which sponsors the I-SPY trial.
PMID 42561946 · 2026Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Alexander reported receiving grants from Pfizer, AstraZeneca, Daiichi Sankyo, Specialised Therapeutics, and Johnson & Johnson, as well as nonfinancial support from Amgen outside the submitted work. Dr Francis reported receiving lecture honoraria from Lilly outside the submitted work. Dr Phillips reported receiving grants from Delos, Versalux, and Beacon outside the submitted work. In addition, Dr. Phillips reported being a founder and director of Circadian Health Innovations outside the submitted work. Dr Wiley reported receiving small royalties for books on data analysis or science as well as one-time payments for statistical workshop delivery (none cancer or sleep related) outside the submitted work. No other disclosures were reported.
PMID 42658497 · 2026A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Coffin reported employment with WCG Clinical and receiving consulting fees from Immunovia for work related to hereditary cancer and pancreatic cancer research and from Brigham and Women's Hospital outside the submitted work. Dr Pratt reported receiving faculty registration and hotel honoraria from the Academy of Oncology Nurse & Patient Navigators Annual Conference outside the submitted work. Dr Leath reported receiving grant support from the National Cancer Institute, grant support for scientific consultation and contracted research from AbbVie–Immunogen, GSK, Merck & Co Inc, Agenus Inc, AstraZeneca, and Volastra Therapeutics Inc, scientific consultation fees from Acrotech and Genmab A/S, and participation on a data safely monitoring board from Imunon Inc outside the submitted work. Dr Frey reported consulting for Wondr Health. Dr Rauh-Hain reported receiving consulting fees from Guidepoint, Sago, AstraZeneca, and Merck & Co Inc outside the submitted work. No other disclosures were reported.
PMID 42658496 · 2026Digital Mental Health Treatment and Symptoms of Depression and Anxiety in Breast Cancer Survivors: A Randomized Clinical Trial.
Conflict of Interest Disclosures: Dr Chow reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Ritterband reported receiving grants from the NIH during the conduct of the study. Prof Mohr reported equity ownership in Adaptive Health during the conduct of the study and receiving personal fees from OpenAI and Benchmark Health outside the submitted work. No other disclosures were reported.
PMID 42475097 · 2026Germline Multigene Panel Testing in Women With Invasive Lobular Cancer.
Conflict of Interest Disclosures: Dr Curigliano reported receiving personal fees from Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Lilly, Menarini, Gilead, Exact Science, Merck, and BMS outside the submitted work. Dr Bertolini reported receiving grants from Menarini outside the submitted work. No other disclosures were reported.
PMID 42418202 · 2026Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
P. Schmid reports grants and personal fees from AstraZeneca, Merck, Novartis, and Roche; personal fees from Bayer, Boehringer Ingelheim, Pfizer, Puma Biotechnology, Eisai, and Celgene; and grants from Astellas, Genentech, OncoGenex, and Medivation outside the submitted work. C.X. Ma reports other support from AstraZeneca during the conduct of the study; C.X. Ma also reports personal fees from AstraZeneca, Puma Biotechnology, Genentech, Bayer Oncology, FoRx, Eli Lilly and Company, Novartis, Stemline, Danatlas, Regor Therapeutics, Merck, and Daiichi Sankyo, as well as grants and personal fees from Pfizer outside the submitted work. Y.H. Park reports nonfinancial support from AstraZeneca during the conduct of the study. Y.H. Park also reports grants, personal fees, nonfinancial support, and other support from AstraZeneca, Gilead Sciences, Helsinn, and Pfizer; personal fees, nonfinancial support, and other support from Daiichi Sankyo, Novartis, and Relay Therapeutics; personal fees from Bristol Myers Squibb and AIMEDBIO; grants, personal fees, and nonfinancial support from Voronoi and Roche; personal fees and nonfinancial support from Menarini, MSD, Jazz, and BeOne; and grants from Daewoong Pharmaceuticals and Inocras outside the submitted work. S. Lord reports other support from AstraZeneca during the conduct of the study. A. Armstrong reports grants from Gilead Sciences (educational grant); personal fees from Menarini, Gilead Sciences, Lilly UK, Novartis, and Roche; and nonfinancial support from Roche, Lilly UK, and Novartis outside the submitted work. S.-A. Im reports grants from AstraZeneca, Boryung Pharmaceutical, Roche, Pfizer, and Daiichi Sankyo; other support from Eisai, SK Biopharmaceuticals, and Daiichi Sankyo; and personal fees and other support from AstraZeneca, MSD, Novartis, Eli Lilly and Company, Pfizer, and Roche outside the submitted work. R. Fernandes reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca, Janssen, Seagen, Ipsen, Novartis, Eisai, Bayer, Pfizer, Astellas, EMD Inc., and IQVIA outside the submitted work. Y.-S. Lu reports grants and personal fees from AstraZeneca, as well as personal fees and nonfinancial support from Daiichi Sankyo during the conduct of the study; Y.-S. Lu also reports grants, personal fees, and nonfinancial support from Novartis, personal fees and nonfinancial support from Roche, and personal fees from Pfizer, Eli Lilly and Company, MSD, and Gilead Sciences outside the submitted work. W.-P. Chung reports personal fees from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Gilead Sciences, Novartis, Pfizer, Roche, Menarini, and MSD outside the submitted work. P. Rao-Melacini reports employment with AstraZeneca Canada with stock options. K. Heider reports other support from AstraZeneca during the conduct of the study. R. Stewart reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work. P. Vuković reports personal fees from AstraZeneca during the conduct of the study. K.H. Jung reports other support from Parexel during the conduct of the study, as well as personal fees from AstraZeneca, Daiichi Sankyo, Roche, Gilead Sciences, Novartis, Daewoong Pharmaceuticals, and ImmuneOncia outside the submitted work. No disclosures were reported by the other authors.
PMID 42189888 · 2026Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.
K. Jhaveri reports personal fees from Novartis, Pfizer, Genentech, AstraZeneca, Daiichi Sankyo, Gilead, Eisai, Blueprint Medicines, Relay Pharmaceuticals, Natera, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck Pharmaceuticals, Zymeworks, Halda Therapeutics, Arivinas, Precede Biosciences, BeOneTherapeutics, Natera, Mersana, ConcertAI, BridgeBio Oncology, and RayzeBio, and other support from MJH Life Sciences, Curio Sciences, MD Education, Clinical Care Options, Aptitude Health, Novartis, Genentech, AstraZeneca, Pfizer, Lilly, Loxo Oncology, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, RayzeBio, Eisai, Bicycle Therapeutics, BridgeBio Oncology Therapeutics, Blueprint Medicines, Breast Cancer Research Foundation, and Fred’s Team and Manhasset Women’s Coalition Against Breast Cancer outside the submitted work. H.S. Rugo reports personal fees from Napo, Bristol Myers Squibb, Helsinn, and BioNTech, and grants from AstraZeneca, Gilead Sciences, Lilly, Merck & Co., Daiichi Sankyo, Novartis, Pfizer, F. Hoffman-La Roche/Genentech, Stemline Therapeutics, Ambryx, Bicycle Therapeutics, PhoenixMD, Relay Therapeutics, ALX Oncology, and Mabwell outside the submitted work. J. Cortés reports personal fees from Gilead during the conduct of the study, as well as grants and personal fees from MSD, Eisai, Pfizer Roche, and AstraZeneca, personal fees and other support from Leuko, personal fees from Seattle Genetics, Daiichi Sankyo, Lilly, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, AbbVie, BridgeBio, BioNTech, Biocon, Circle Pharma, Delcath Systems, Hexagon Bio, Bliss Biopharmaceuticals, Relay Therapeutics, Novartis, and Zuellig Pharma, grants from Ariad Pharmaceuticals, Baxalta, Bayer Healthcare, Guardant Health, Piqur Therapeutics, Iqvia, Queen Mary University of London, and other support from MAJ3 Capital outside the submitted work; in addition, J. Cortes has a patent for “Pharmaceutical combinations of a Pi3k inhibitor and a microtubule-destabilizing agent” (J. Cortes, Alejandro Piris Gimenez, Violeta Serra Elizalde. WO 2014/199294 A) issued and a patent for “Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy” (Aleix Prat, Antonio Llombart, J. Cortes. US 2019/0338368 A1) licensed. M. Oliveira reports grants, personal fees, and nonfinancial support from AstraZeneca during the conduct of the study, as well as personal fees from Daiichi Sankyo, Lilly, MSD, ProteinQure, Curio Science, and iOne, grants from Immutep, and grants, personal fees, and nonfinancial support from Gilead, Pfizer, and Roche outside the submitted work. S.J. Howell reports grants, personal fees, and nonfinancial support from Eli Lilly, and personal fees and nonfinancial support from AstraZeneca, Novartis, Pfizer, and Menarini outside the submitted work. F. Dalenc reports nonfinancial support from Gilead, Novartis, Pfizer, Daiichi Sankyo, and AstraZeneca during the conduct of the study. S. Loibl reports grants and other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca, AbbVie, Agendia, Amgen, BioNTech, Celgene, Bristol Myers Squibb, Cellcuity, DSI, Exact Sciences, Gilead, GSK, Incyte, Lilly, Medscape, Molecular Health, MSD, Novartis, Pierre Fabre, Pfizer, Relay, Roche, Sanofi, Seagen, Stemline Menarini, Olema, Bayer, Bicycle, Jazz Pharmaceuticals, BeiGene, Jiangsi Hengrui, MICE Ideas, Corcept Therapeutics, Peerview, AICME, and Chugai Pharmaceuticals outside the submitted work; in addition, S. Loibl has a patent for EP14153692.0 pending, a patent for EP21152186.9 pending, a patent for EP18209672 pending, a patent for EP24210258 pending, and a patent for VM Scope with royalties paid. Y.H. Park reports grants, personal fees, and nonfinancial support from AstraZeneca, Novartis, Pfizer, and Roche, personal fees and nonfinancial support from Gilead, RLY Therapeutics, Lilly, MSD, Jazz, and Daiichi Sankyo, grants and nonfinancial support from Helsinn and Voronoi, personal fees from Bristol Myers Squibb, AimedBio, and BeONE, grants from Inocras and Daewoong, and nonfinancial support from Sanofi, Menarini, and ALX Oncology outside the submitted work. J. Sohn reports grants from MSD, Roche, Novartis, Lilly, Pfizer, Daiichi Sankyo, AstraZeneca, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, Seagan, Qurient, Dragonfly, Eikon, Gilead, Bristol Myers Squibb, HLB Life Science, Sermonix Pharmaceuticals, Olema, Hanmi Pharm, Ildong Pharmaceutical, Samyang Holdings, and Centessa Pharmaceutical during the conduct of the study, as well as other support from Daiichi Sankyo outside the submitted work. M. Toi reports personal fees from Chugai, Pfizer, Taiho, Devicore Medical Japan, Yakult, Novartis, Eisai, Eli Lilly, AstraZeneca, Daiichi Sankyo, and Kansai Medical Net outside the submitted work. E. Tokunaga reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from Eli Lilly, Daiichi Sankyo, Gilead, and Chugai outside the submitted work. A. Nardone reports other support from AstraZeneca during the conduct of the study and outside the submitted work. I. Wadsworth reports employment with PHASTAR, which performed the work on this manuscript under a contract with AstraZeneca. D. Das reports employment with AstraZeneca and holds AstraZeneca shares. E.C. de Bruin reports employment with AstraZeneca and holds AstraZeneca shares. N.C. Turner reports advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche/Genentech, Novartis, GlaxoSmithKline, Repare Therapeutics, Inivata, Guardant Health, and Exact Sciences, and research funding from AstraZeneca, Pfizer, Roche/Genentech, MSD, Guardant Health, Invitae, Inivata, Personalis, Natera, and Labcorp. No disclosures were reported by the other authors.
PMID 42154572 · 2026A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
H. Tovey reports grants from Cancer Research UK during the conduct of the study, as well as grants from AstraZeneca, Minderoo Foundation, and Eli Lilly and Company outside the submitted work. S. Barrington reports grants from the National Institute of Health Research and Social Care UK outside the submitted work. J. Bliss reports grants from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Pfizer, Janssen Pharmaceuticals/Cilag, Novartis, Eli Lilly and Company, Breast Cancer Now, Breast International Group, GlaxoSmithKline, Kortuc, and Verastem Oncology outside the submitted work. A. Tutt reports other support from AstraZeneca, Page Therapeutics, Ellipses Pharma, Tango Therapeutics, Guardant Health, and Merck KGaA during the conduct of the study, as well as personal fees from AstraZeneca, FoRx Therapeutics, Nuage Therapeutics, and Artera; grants from AstraZeneca, Myriad Genetics, and Merck KGaA; and other support from AstraZeneca outside the submitted work. In addition, A. Tutt reports benefits from ICR’s Rewards to Discoverers Scheme associated with patents for PARP inhibitors in BRCA1/2-associated cancers, paid into research accounts at The Institute of Cancer Research and to A. Tutt’s personal account. No disclosures were reported by the other authors.
PMID 42048392 · 2026Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.
Dr. Williams: Consultant – Elucent Medical (Eden Prairie, MN)
PMID 42667265 · 2026Development of the cf-MMSP Assay for Enhanced Analytical Sensitivity of Methylated DNA in Breast Cancer Liquid Biopsy.
Conflict of interest disclosure statement: M.J. Fackler has a patent to US10,450,609B2 issued, a patent to US20200190586A1 pending, a patent to CN104520442B issued, a patent to AU2013266341B2 issued, a patent to JP6543569B2 issued, a patent to EP2852690B1 issued, a patent to CA2874035A1 issued, a patent to US8062849B2 issued, a patent to US8822155B2 issued, and a patent to US9416404B2 issued. L.M. Cope has a patent to C11625, “Methylation markers for stratifying breast cancer, for prognosis, for predicting disease recurrence and response to treatment” US 10,316,361 issued. A.C. Wolff reports a patent to C12014. “A Quantitative Multiplex Methylation Specific PCR Method-cMethDNA, Reagents, and Its Use” (license terminated by Cepheid in 2020). V. Stearns reports grants from Abbvie, Novartis, Pfizer, and Puma outside the submitted work; and is advisory board member of Novartis; Chair, DSMB: AstraZeneca. S. Sukumar reports grants, personal fees, and non-financial support from Cepheid, #90066820; grants from DOD, BC220929, in addition, S. Sukumar has a patent to 14,402,434 issued, a patent to 8,822,155 issued, licensed, and with royalties paid, a patent to 8,062,849 issued, licensed, and with royalties paid, a patent to 7,858,317 issued, licensed, and with royalties paid, a patent to 6,835,541 issued, licensed, and with royalties paid, a patent to 6,756,200 issued, licensed, and with royalties paid, a patent to C14473 pending, a patent to C12014 pending, a patent to US 10,316,361 issued, a patent to US 10,450,609B2 pending and issued, a patent to US 20200190586A1 issued, a patent to CN 104520442B pending, a patent to AU 2013266341B2 pending, a patent to JP 6543569B2 pending, a patent to EP 2852690B1 pending, a patent to CA 2874035A1 pending, a patent to US 8062849B2 pending, a patent to US 8822155B2 pending, and a patent to US 9416404B2 pending; No other disclosures were reported.
PMID 42334419 · 2026Consistency of efficacy and safety of elinzanetant for vasomotor symptoms and sleep disturbance associated with menopause across different populations: a review of the OASIS clinical trial program.
Declaration of competing interest JoAnn V. Pinkerton reports nonfinancial support, consulting fees, and grants from Bayer Pharmaceuticals during the conduct of the study as well as consulting fees from Merck and Pfizer outside the submitted work. James A. Simon reports consulting fees from Bayer Healthcare during the conduct of the study as well as grants from AbbVie, Mylan/Viatris, and Myovant Sciences; consulting/advisory board fees from Ascend Therapeutics, Besins Healthcare, Biote Medical, LLC, Femasys, Mayne Pharma, Pfizer, and Vella Bioscience; service on speaker's bureaus for Ascend Therapeutics, Mayne Pharma, Myovant Sciences, and Pharmavite LLC; and being a stockholder in Sermonix Pharmaceuticals outside the submitted work. Nick Panay reports research support from Bayer during the conduct of the study as well as personal fees from Abbott, Astellas, Bayer, Besins, Gedeon Richter, Novo Nordisk, SeCur, Theramex, and Viatris outside the submitted work. Rossella E. Nappi reports personal fees from Abbott, Astellas, Bayer Healthcare, Besins Healthcare, Exeltis, Gedeon Richter, Ibsa, Merck & Co, Novo Nordisk, Organon, Shionogi, Theramex, Viatris, grants from Fidia, and serving as the president of the International Menopause Society outside the submitted work. Donal J. Brennan reports research support from Bayer during the conduct of the study as well as has acted in an advisory capacity for Merck, GSK, AstraZeneca, Bayer, Astellas; received research funding from Pfizer, GSK, AstraZeneca, Bayer; and received Honoraria from Bayer, Medtronic, Olympus, MSD, RAND Biotech. Gilbert Donders has acted in an advisory capacity for and/or received research funding from Medinova, Bayer, Astellas, GSK, MSD, Mycovia, Purna pharmaceuticals, Limmatech, and Gedeon Richter. Claudio N. Soares reports grants from Eisai, Otsuka, Ontario Brain Institute, and Diamond Therapeutics and personal fees from Astellas and Bayer outside the submitted work. Pauline Maki reports personal fees from Astellas, Bayer, and Pfizer, service as a trustee and secretary of the International Menopause Society, and equity in Respin, MidiHealth, and Estrigenix outside the submitted work. Fatima Cardoso declares paid consultancy for: Amgen, Astellas/Medivation, AstraZeneca, Bayer, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime. Cecilia Caetano, Claudia Haberland, Kaisa Laapas, and Lineke Zuurman are all employees of Bayer.
PMID 42537360 · 2026Daily Cherenkov Imaging to Monitor for Unintended Field Overlap During Bilateral Breast Radiation Therapy.
Disclosures Savannah M. Decker was a consultant for DoseOptics, LLC, which provided hardware and software support for this study. The other authors declare no financial interests/personal relationships, which may be considered as potential competing interests:
PMID 41864282 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026
PMID 41342823DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
PMID 42289007Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025
PMID 39636577Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
PMID 42425164[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026
PMID 42296659AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
PMID 42173036Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026
PMID 41996183Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026
PMID 41784888ACR Appropriateness Criteria® Breast Imaging During Lactation.
Journal of the American College of Radiology : JACR · 2026
PMID 41885663Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.
Journal of neuro-oncology · 2026
PMID 42550373Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment.
Applied health economics and health policy · 2026
PMID 42213316Targeted axillary dissection in the primary surgery setting for node-positive breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
PMID 4206869602
Highest-Priority Research
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rhythm Society members, including EP physicians and nonphysician members (nurses, technologists, allied professionals, and clinical specialists). The survey collected data on health …
PMID 41342823DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
AIM: The aim of this work is to update the practical guidelines for adjuvant radiotherapy of the regional lymphatics in breast cancer, originally issued in 2014 by the Breast Cancer Expert Panel of the German Society of Radiation Oncology. METHODS: A comprehensive literature review concerning regional nodal irradiation (RNI) was performed using the search terms "breast cancer," "radiotherapy," and "regional node irradiation." Furthermore, data from recently published meta-analyses and international breast cancer society guidelines-providing new insights since 2014-served as the basis for defining evidence-based recommendations. This paper delineates the indications and dose-fractionation str…
PMID 42289007Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous variable, influenced by family history and other modifiers. ATM GPV heterozygotes should generally be offered enhanced breast surveillance according to their personalized risk est…
PMID 39636577Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026
The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factor…
PMID 42425164[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026
Metastatic breast cancer (mBC) has become a chronic disease for a growing number of women thanks to therapeutic advances, generating a new population of patients with prolonged response. This article, written by experts in oncology and primary care (PC) in Spain, offers practical recommendations for the comprehensive management of these patients. It addresses strategies to improve therapeutic compliance, the detection and management of toxicities, the early identification of signs of progression, and the management of comorbidities and drug interactions. In addition, it emphasizes the importance of psychosocial support, the promotion of healthy habits, and coordination between oncology and P…
PMID 42296659AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the ommission of sentinel lymph node biopsy (SLNB) and preffered axillary staging in patients with node-positive breast cancer undergoing neoadjuvant chemotherapy (NACT). Targeted axillary dissection (TAD) is endorsed as the method of choice [AGO ++] in patients converting from cN + to ycN0 status, and other de-es…
PMID 42173036Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026
BACKGROUND: Timely surgery is a key determinant of breast cancer outcomes; however, prior studies are inconsistent due to heterogeneous treatment pathways and inclusion of neoadjuvant therapy populations. The prognostic impact of delays to upfront surgery remains unclear. We evaluated the association between time from diagnosis to upfront surgery and survival in invasive breast cancer. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, and additional sources was conducted through April 25, 2025. Quantitative studies in English or French assessing time to upfront surgery and prognosis were included; neoadjuvant cohorts were excluded. Two reviewers independently screened studies. Random…
PMID 42315709Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026
DESCRIPTION: The purpose of this updated guidance statement is to guide internal medicine physicians and other clinicians on screening for breast cancer in asymptomatic, average-risk adult females. METHODS: The American College of Physicians updated its guidance statement on screening for breast cancer using high-quality clinical guidelines from national guideline developers around the world. GUIDANCE STATEMENT 1: In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk of breast cancer, values and preferences, and uncertainty around benefits and harms of screening for breast cancer. Following shared decision making, if a female in this populatio…
PMID 41996183Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026
To enhance the quality of organized mammographic screening in Italy, in accordance with national legislation, a multidisciplinary panel of experts applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)-ADOLOPMENT approach to adopt or adapt the European Commission Initiative on Breast Cancer (ECIBC) guidelines concerning the use of digital breast tomosynthesis (DBT). As prerequisite conditions for DBT adoption, the panel defines a full extension to women in the 45-74 age range, sufficient technical and professional resources, and an adequate monitoring system. The panel recommends the use of either DBT or digital mammography (DM) for asymptomatic women particip…
PMID 41784888Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial, NIH-AARP Diet and Health, we predicted BMI throughout adulthood. We landmarked to predefined ages of interest (AOI), ages 30 to 65 (5-yearly). Super-landmarking and a two-…
PMID 41952250ACR Appropriateness Criteria® Breast Imaging During Lactation.
Journal of the American College of Radiology : JACR · 2026
This article provides evidence-based guidance for imaging lactating women across screening, diagnostic, and staging scenarios. Imaging should not be deferred because of lactation; mammography with digital breast tomosynthesis, targeted ultrasound, and contrast-enhanced MRI have defined roles based on age, presenting complaint, and cancer risk and may be used similarly to nonlactating patients. Physiologic changes during lactation can alter breast appearance and complicate clinical and imaging assessment. Gadolinium contrast and most nuclear medicine procedures result in negligible infant exposure and do not require interruption of breastfeeding. Image-guided core biopsy and aspiration are sa…
PMID 41885663Post-Diagnostic Diet and Breast Cancer Outcomes: A Comprehensive Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
Nutrients · 2026
Background/Objectives: Diet is increasingly recognized as a modifiable factor in cancer survivorship; however, the impact of post-diagnostic dietary habits on breast cancer (BC) outcomes remains uncertain. This systematic review aimed to evaluate the association between diet after BC diagnosis and clinical outcomes and to provide an updated synthesis of the evidence, with particular emphasis on dietary assessment methods, methodological heterogeneity, and evidence gaps. Methods: We systematically reviewed randomized controlled trials (RCTs) and prospective cohort studies that investigated post-diagnostic dietary exposures among women with BC. Outcomes of interest included all-cause mortality…
PMID 4265416603
Latest Research — Last 24 Months
2027
2027
2027
2026
Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · PMID 42315709
2026
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · PMID 42030172
2026
2026
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · PMID 41765743
2026
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · PMID 42289089
2026
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · PMID 42530793
2026
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · PMID 41396594
2026
MIF -173 G>C polymorphism as a context-dependent modifier of solid cancer risk: A meta-analysis.
Cancer treatment and research communications · PMID 42673731
2026
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Expert opinion on drug safety · PMID 39960238
2026
Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis.
Frontiers in oncology · PMID 42666138
2026
Current evidence on the prospective predictors and trajectories of posttraumatic growth and depreciation in adult women with breast cancer: a systematic review of longitudinal studies.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · PMID 42576029
2026
Mapping interventions to increase uptake of breast and cervical cancer screening along the Intervention Ladder: a systematic review.
Health psychology review · PMID 41637206
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
moderate-confidence evidence
Antineoplastic Agents
57 linked PMIDs15586 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, recurrence, progression-free survival, mortality, adverse events, recurrence-free survival
- Populations represented
- general population; triple-negative breast cancer; BRCA1; HER2; metastatic; metastatic breast cancer; advanced; metastatic; HER2; PIK3CA
- Mechanism
- Targeting AC008406.3 may represent a potential strategy to sensitize breast cancer cells to DTX Chemical probes are an indispensable tool for translating biological discoveries into new therapies, though are increasingly difficult to identify since novel therapeutic targets are often hard-to-drug proteins
preliminary evidence
Biomarkers, Tumor
42 linked PMIDs27809 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, progression-free survival, objective response rate, response rate, adverse events, overall survival, disease-free survival
- Populations represented
- general population; triple-negative breast cancer; HER2; metastatic breast cancer; locally advanced; advanced; metastatic; HER2; PIK3CA; hormone receptor-positive breast cancer; triple-negative breast cancer; metastatic; ER; PR; HER2; PIK3CA
- Mechanism
- PURPOSE: Functions associated with glycolysis could serve as targets or biomarkers for therapy cancer The identified hub genes represent promising biomarkers and potential therapeutic targets warranting further investigation
preliminary evidence
Erb-b2 Receptor Tyrosine Kinases
25 linked PMIDs53790 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, adverse events, progression-free survival, disease-free survival, objective response rate, response rate, recurrence-free survival
- Populations represented
- HER2; metastatic breast cancer; metastatic; HER2; early-stage; HER2; advanced; ER; HER2; metastatic breast cancer; locally advanced; advanced; metastatic; HER2; triple-negative breast cancer; metastatic; ER; PR; HER2; PIK3CA
- Mechanism
- Emerging evidence indicates that dysregulated lipid metabolism plays a critical role in tumorigenesis and metastasis, suggesting that targeting lipid metabolism may represent a promising therapeutic strategy Mechanistically, STARD10 was found to drive malignant phenotypes via activation of the cAMP/PKA/CREB1 signaling axis
preliminary evidence
ERBB2 protein, human
19 linked PMIDs53380 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival, adverse events, disease-free survival, objective response rate, response rate, cardiotoxicity
- Populations represented
- HER2; metastatic breast cancer; metastatic; HER2; early-stage; HER2; metastatic breast cancer; locally advanced; advanced; metastatic; HER2; HER2-positive breast cancer; HER2; triple-negative breast cancer; metastatic breast cancer; metastatic; HER2
- Mechanism
- Emerging evidence indicates that dysregulated lipid metabolism plays a critical role in tumorigenesis and metastasis, suggesting that targeting lipid metabolism may represent a promising therapeutic strategy Mechanistically, STARD10 was found to drive malignant phenotypes via activation of the cAMP/PKA/CREB1 signaling axis
preliminary evidence
endocrine therapy
18 linked PMIDs36608 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, recurrence, mortality, disease-free survival, adverse events
- Populations represented
- general population; hormone receptor-positive breast cancer; ER; HER2; metastatic; first-line; early-stage; ER; HER2; ER; PR
- Mechanism
- Evidence regarding glucagon-like peptide-1 (GLP-1) receptor agonists in this specific context remains limited Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initiated and titrated to 3.0 mg/day
higher-confidence evidence
radiotherapy
17 linked PMIDs276942 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, overall survival
- Populations represented
- general population; triple-negative breast cancer; stage I; stage II; stage I; stage II; HER2
- Mechanism
- This paper delineates the indications and dose-fractionation strategies for radiotherapy targeting the regional lymphatic pathways following breast cancer surgery The combination of ionomycin and radiotherapy resulted in inhibition of the proliferation of breast cancer cells in vitro experiments, which was indicated by cell counting kit-8 and colony formation experiments
moderate-confidence evidence
Receptors, Estrogen
10 linked PMIDs52199 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, recurrence, reported clinical outcomes, overall survival, disease-free survival, pathological complete response
- Populations represented
- advanced; ER; HER2; ER; HER2; hormone receptor-positive breast cancer; PR; HER2; ER; ER; PR; HER2; early-stage breast cancer; early-stage; stage I
- Mechanism
- Population pharmacokinetic (PK) and exposure-response analyses were performed to characterize the PK and exposure-response relationships of vepdegestrant, a first-in-class, oral PROteolysis-TArgeting Chimera estrogen receptor degrader PURPOSE: Vepdegestrant is an investigational, orally administered PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader being evaluated for the treatment of ER+/HER2- advanced breast cancer, with promising results in prior studies of Western and Japanese patients
limited evidence
tamoxifen
10 linked PMIDs154 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, mortality
- Populations represented
- general population; ER; ER; PR
- Mechanism
- These findings highlight the intricate relationship between TAM, gut microbiota, and BA metabolism, suggesting that targeting the gut-liver FXR axis with HDCA may serve as a promising therapeutic strategy for alleviating TAM-associated liver injury Evidence regarding glucagon-like peptide-1 (GLP-1) receptor agonists in this specific context remains limited
preliminary evidence
Trastuzumab
8 linked PMIDs8727 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, objective response rate, response rate, adverse events
- Populations represented
- metastatic breast cancer; metastatic; HER2; general population; triple-negative breast cancer; metastatic breast cancer; metastatic; HER2; HER2-positive breast cancer; localized; HER2; metastatic breast cancer; metastatic; first-line; HER2
- Mechanism
- Pathologists should exercise caution when assigning IHC 0, and practical measures such as reflexive re-evaluation, re-staining of alternative blocks, and referral to high-sensitivity laboratories are recommended
limited evidence
Protein Kinase Inhibitors
8 linked PMIDs20 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, disease-free survival, recurrence, progression-free survival, adverse events
- Populations represented
- general population; early-stage breast cancer; early-stage; metastatic; first-line; metastatic breast cancer; advanced; metastatic; HER2; PIK3CA; advanced
- Mechanism
- Unlike conventional ATP-competitive inhibitors that target the kinase domain, selective inhibition of PLK1's polo-box domain (PBD) offers a promising strategy to disrupt protein-ligand interactions critical for mitotic progression, thereby triggering apoptosis in cancer cells While virtual docking and in silico ADMET-S assessments cannot definitively confirm selectivity or mechanism of action, this study generates testable hypotheses and prioritizes a focused set of natural-product-derived candidates for future molecular dynamics simulations, biochemical validation, or experimental screening
limited evidence
Reactive Oxygen Species
8 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population; metastatic; advanced
- Mechanism
- However, their tendency to form lipid-bound structures in circulation limits their tumor-targeting therapeutic potential and raises the risk of off-target effects In contrast, the exposure to the tumor microenvironment, which is characterized by low pH and elevated ROS, could trigger a conformational transition to a structured α-helical state, thereby enhancing its membrane-disruptive and tumor-targeting capabilities
preliminary evidence
breast-conserving surgery
7 linked PMIDs274238 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, pathological complete response, overall survival
- Populations represented
- general population; locally advanced; advanced; HER2; stage I; stage II; HER2; advanced
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Contrast Media
7 linked PMIDs1044 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antibodies, Monoclonal, Humanized
7 linked PMIDs646 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, disease-free survival, objective response rate, response rate, pathological complete response, adverse events, progression-free survival
- Populations represented
- triple-negative breast cancer; triple-negative breast cancer; early-stage; stage II; metastatic breast cancer; advanced; metastatic; HER2; triple-negative breast cancer; advanced; metastatic; previously treated; metastatic breast cancer; metastatic; first-line; HER2; triple-negative breast cancer; metastatic; PD-L1
- Mechanism
- BACKGROUND: TQB2102 is a next-generation biparatopic antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) extracellular domain 2 (ECD2) and ECD4 epitopes that is conjugated to a topoisomerase I inhibitor via an enzyme-cleavable linker
preliminary evidence
Fluorodeoxyglucose F18
7 linked PMIDs540 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence
- Populations represented
- triple-negative breast cancer; stage II; general population; metastatic; treatment-naive; metastatic; metastatic breast cancer; metastatic; locally advanced; advanced
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Gold
7 linked PMIDs156 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population; localized; triple-negative breast cancer
- Mechanism
- The platform's high specificity is attributed to the programmable crRNA design, enabling detection of specified DNA sequences and showcasing significant adaptability for diagnosing multiple genetic targets, highlighting its potential in clinical cancer diagnosis Thermal damage to surrounding healthy tissues poses a challenge in photothermal therapy (PTT) due to the limited targeting efficiency
preliminary evidence
MicroRNAs
7 linked PMIDs147 reported cumulative sample signal
- Research status
- mostly supportive
- Outcomes represented
- reported clinical outcomes, mortality
- Populations represented
- general population; triple-negative breast cancer
- Mechanism
- Mechanistically, miR-3664-5p targets PGM5P4-AS1/KLF9 directly, and KLF9 silencing reverses the cellular function inhibition caused by miR-3664-5p downregulation Breast cancer (BRCA) development is tightly linked to metabolic dysregulation, with enhanced aerobic glycolysis standing out as a key hallmark, and competing endogenous RNA (ceRNA) mechanisms have emerged as critical epigenetic regulators of tumor metabolic pathways-this study thus aimed to explore glycolytic regulation through ceRNA networks in BRCA, with the goal of identifying potential prognostic biomarkers and mechanistic targets
moderate-confidence evidence
Paclitaxel
6 linked PMIDs386 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence, progression-free survival, objective response rate, response rate, adverse events
- Populations represented
- general population; triple-negative breast cancer; hormone receptor-positive breast cancer; PR; HER2; triple-negative breast cancer; metastatic; PD-L1; triple-negative breast cancer; locally advanced; advanced; metastatic; first-line; PIK3CA; PD-L1
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
05
Conflicting Research
limited evidence
10 studiesContrast Media · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 8null: 1benefit: 1
higher-confidence evidence
4 studiesERBB2 protein, human · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic breast cancer; locally advanced; advanced; metastatic; HER2. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 3mixed: 1
higher-confidence evidence
4 studiesErb-b2 Receptor Tyrosine Kinases · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic breast cancer; locally advanced; advanced; metastatic; HER2. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 3mixed: 1
06
Failed or Negative Trials
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
randomized controlled trial · 2026 · PMID 42508432
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.
randomized controlled trial · 2026 · PMID 42551036
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
randomized controlled trial · 2026 · PMID 41937088
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
randomized controlled trial · 2026 · PMID 41934626
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
randomized controlled trial · 2026 · PMID 42372743
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
randomized controlled trial · 2026 · PMID 42350643
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.
randomized controlled trial · 2026 · PMID 42275799
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
randomized controlled trial · 2026 · PMID 42613139
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.
randomized controlled trial · 2026 · PMID 42364416
Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival.
randomized controlled trial · 2026 · PMID 42210709
07
Emerging and Experimental Research
Ultrasound-induced cascade nanozyme catalysis for enhanced tumor cell pyroptosis and systemic anti-tumor immunity.
preclinical or laboratory · 2027 · PMID 42537459
Tumor microenvironment-responsive self-assembling nanotherapeutics integrating chemo-, anti-angiogenic, and immunostimulatory therapy for triple-negative breast cancer.
preclinical or laboratory · 2027 · PMID 42462535
The Effects of Guided Imagery on Women's Health: A Systematic Review of Experimental Studies.
systematic review · 2026 · PMID 42652381
Digital Health Interventions and Psychosocial Outcomes in Women With Breast Cancer: Systematic Review.
systematic review · 2026 · PMID 42627958
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.
randomized controlled trial · 2026 · PMID 42492022
French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
randomized controlled trial · 2026 · PMID 42665344
Effectiveness of Sentimag technology (Magseed and Magtrace localization) compared to traditional care for the management of early breast cancer: a systematic review protocol.
systematic review · 2026 · PMID 41536188
The Effect of Virtual Reality on Chemotherapy-Associated Stress (Cortisol Value), Anxiety, and Pain Symptoms of Mastectomy Patients: A Randomized Controlled Pilot Study.
randomized controlled trial · 2026 · PMID 40179266
A laddered training model for breast surgery specialists: development and validation of a CBME-based precision education framework.
randomized controlled trial · 2026 · PMID 42321739
Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation.
randomized controlled trial · 2026 · PMID 42594101
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care95 records
Rank116.0
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
Annals of oncology : official journal of the European Society for Medical Oncology · 2021 · PMID 34242744
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this important bi-annual critical review of the 'state of the art' in the multidisciplinary care of early-stage breast cancer. Seventy-four expert panelists (see Appendix 1) from all continents discussed and commented on the previously elaborated consensus questions, as well as many key questions on early breast cancer diagnosis and treatment…
Rank115.9
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026 · PMID 41342823
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rh…
Rank112.0
Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025 · PMID 39636577
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous…
Rank112.0
DEGRO practical guidelines: radiotherapy of breast cancer-regional nodal irradiation.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026 · PMID 42289007
AIM: The aim of this work is to update the practical guidelines for adjuvant radiotherapy of the regional lymphatics in breast cancer, originally issued in 2014 by the Breast Cancer Expert Panel of the German Society of Radiation Oncology. METHODS: A comprehensive literature review concerning regional nodal irradiation (RNI) was performed using the search terms "breast cancer," "radiotherapy," and "regional node irradiation." Furthermore, data from recently published meta-analyses and international breast cancer so…
Rank112.0
[Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].
Magyar onkologia · 2025 · PMID 41002090
AIM: To formulate standardized recommendations for recognizing and managing the genetic risk of breast cancer, based on the latest scientific evidence and clinical experience. METHODS: The authors adapted international professional guidelines to local conditions, which were reviewed within the framework of the 5th Hungarian Breast Cancer Consensus Conference. RESULTS: The consensus document provides detailed guidance on the indications for genetic testing, the process of clinical genetic counseling, and hereditary …
Rank112.0
[Breast cancer survivor program: follow-up, rehabilitation, psycho-oncology, palliative care].
Magyar onkologia · 2025 · PMID 41002089
This recommendation based on recent international guidelines, literature data and our experience deals with the follow-up, complex rehabilitation, palliative and nutritional therapy of breast cancer patients. Practising intensive follow-up is not justified but early detection and curative management of local/regional tumor relapse is still a priority, while special issues (breast cancer risk, pregnancy) must be handled with expertise. Social rehabilitation should be advised by competent social workers. Various diag…
Rank110.0
[Systemic treatment of breast cancer: professional guideline].
Magyar onkologia · 2025 · PMID 41002088
Over the years since the 4th Breast Cancer Consensus Conference, a substantial body of new evidence based on clinical trial results has been published, necessitating an update of the 2020 recommendations. This professional guideline primarily reflects the current ESMO, NCCN, ABC, and St. Gallen Consensus Conference statements and recommendations. From a didactic perspective, the text first addresses early-stage breast cancer, followed by locally advanced, locoregionally recurrent, and metastatic breast cancer. At t…
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank110.0
Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2).
Annals of internal medicine · 2026 · PMID 41996183
DESCRIPTION: The purpose of this updated guidance statement is to guide internal medicine physicians and other clinicians on screening for breast cancer in asymptomatic, average-risk adult females. METHODS: The American College of Physicians updated its guidance statement on screening for breast cancer using high-quality clinical guidelines from national guideline developers around the world. GUIDANCE STATEMENT 1: In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk…
Rank110.0
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42173036
The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the ommission of sentinel lymph node biopsy (SLNB) and preffered axillary staging in patients with node-positive breast cancer undergoi…
Rank110.0
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 42425164
The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget's disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV …
Rank110.0
[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026 · PMID 42296659
Metastatic breast cancer (mBC) has become a chronic disease for a growing number of women thanks to therapeutic advances, generating a new population of patients with prolonged response. This article, written by experts in oncology and primary care (PC) in Spain, offers practical recommendations for the comprehensive management of these patients. It addresses strategies to improve therapeutic compliance, the detection and management of toxicities, the early identification of signs of progression, and the management…
Rank110.0
S1 guideline sweat gland carcinoma.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026 · PMID 42412045
The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle-aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features. The tumors are usually located in the head and neck area and on extremities, with the exception of extramammary Paget's carcinoma, which has an anogenital predilection. Sweat gland carc…
Rank110.0
ACR Appropriateness Criteria® Breast Imaging During Lactation.
Journal of the American College of Radiology : JACR · 2026 · PMID 41885663
This article provides evidence-based guidance for imaging lactating women across screening, diagnostic, and staging scenarios. Imaging should not be deferred because of lactation; mammography with digital breast tomosynthesis, targeted ultrasound, and contrast-enhanced MRI have defined roles based on age, presenting complaint, and cancer risk and may be used similarly to nonlactating patients. Physiologic changes during lactation can alter breast appearance and complicate clinical and imaging assessment. Gadolinium…
Rank110.0
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41671423
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and p…
Rank110.0
Italian guidelines for the use of digital breast tomosynthesis in breast cancer screening programmes: GRADE-ADOLOPMENT of the European guidelines.
La Radiologia medica · 2026 · PMID 41784888
To enhance the quality of organized mammographic screening in Italy, in accordance with national legislation, a multidisciplinary panel of experts applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE)-ADOLOPMENT approach to adopt or adapt the European Commission Initiative on Breast Cancer (ECIBC) guidelines concerning the use of digital breast tomosynthesis (DBT). As prerequisite conditions for DBT adoption, the panel defines a full extension to women in the 45-74 age range, suffic…
Rank109.7
Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.
Journal of neuro-oncology · 2026 · PMID 42550373
PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcomes, guidelines, and ongoing trials in TNBC-associated BM. METHODS: The review followed PRISMA guidance and was registered in the Open Science Framework (OSF.IO/6TDRF). MEDLINE, Scopus, Web of Science, DOAJ, and ClinicalTrials.gov we…
Rank104.2
Health Economic Evaluations of Breast Cancer Screening Strategies: A Systematic Review Focusing on Methodology and Quality Assessment.
Applied health economics and health policy · 2026 · PMID 42213316
BACKGROUND: Breast cancer screening is vital for early detection and improved health outcomes but requires robust health economic evaluations to guide implementation. This systematic review examines the methodology, quality, and results of health economic evaluations of screening strategies to support decision making and future research. METHODS: A literature search was performed in PubMed, Embase, Web of Science, EconLit, and the HTA database. Health economic evaluations of breast cancer screening strategies using…
Rank103.6
Targeted axillary dissection in the primary surgery setting for node-positive breast cancer: A systematic review.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42068696
INTRODUCTION: Targeted axillary dissection (TAD) improves the accuracy of axillary staging in patients undergoing neoadjuvant chemotherapy but its role in patients with low volume nodal disease undergoing primary surgery is unclear. This study aimed to summarise the evidence of upfront TAD in the primary surgical setting in patients with node-positive breast cancer. METHODS: Searches were performed in PubMed, Embase, and Scopus to identify studies reporting the outcomes of upfront TAD in patients with node-positive…
Rank102.6
Breast Lesions in Women ≤ 40 Years: Diagnostic Accuracy and Risk of Malignancy of Fine Needle Aspiration Cytology Based on the World Health Organization Breast Cytology Reporting System-A Systematic Review and Meta Analysis.
Diagnostic cytopathology · 2026 · PMID 42204730
INTRODUCTION: Breast cancer is the most common malignancy and the leading cause of cancer deaths among women worldwide. Diagnostic vigilance is vital as malignant cases in young women show higher proliferation and lower hormone-regulated gene expression, indicating more aggressive cases. The proposed IAC-IARC-WHO reporting system will adopt and update the current IAC Yokohama System for reporting breast cytology, which has five categories. This review evaluates the diagnostic accuracy of FNAC in women aged ≤ 40 usi…
Rank100.0
Comparison efficacy and safety of acupuncture and moxibustion therapies in breast cancer-related lymphedema: A systematic review and network meta-analysis.
PloS one · 2024 · PMID 38743748
OBJECTIVE: Although several acupuncture and moxibustion therapies have been tested in managing breast cancer-related lymphedema (BCRL), there is little consensus regarding the best options for treating this condition. This systematic review and network meta-analysis compared the efficacy of various acupuncture and/or moxibustion therapies for BCRL. METHODS: Seven databases and two clinical registration centers were searched from their inception to December 1st, 2023. The Cochrane Collaboration risk-of-bias assessme…
Rank100.0
Measures of Thriving in Breast Cancer: A COSMIN Systematic Review of Psychometric Properties.
Oncology nursing forum · 2026 · PMID 42690383
PROBLEM IDENTIFICATION: Thriving, a construct reflecting personal growth, resilience, and emotional vitality after adversity, is gaining attention in oncology and health-related quality-of-life research. However, consensus is lacking on which patient-reported outcome measures (PROMs) best assess thriving in individuals with breast cancer. LITERATURE SEARCH: A systematic search across nine databases identified studies reporting the development or psychometric evaluation of PROMs for thriving in adults. DATA EVALUATI…
Rank100.0
RGS Family Remodeling in Breast Cancer: A Meta-Analysis and Multi-Omics Profiling of Prognostic Biomarkers.
Cancer medicine · 2026 · PMID 42520291
BACKGROUND: Breast cancer (BC) is a heterogeneous malignancy with diverse molecular subtypes and variable clinical outcomes. Despite diagnostic and therapeutic advances, recurrence and metastasis contribute to poor prognosis in subsets of patients. Regulators of G protein signaling (RGS) proteins, negative modulators of G protein-coupled receptor (GPCR) pathways, influence tumor progression, but their expression profiles, genomic alterations, immune associations, and prognostic roles in BC remain incompletely under…
Rank100.0
Economic Evaluation of Breast Cancer Screening in China: A Systematic Review of Costs and Cost-Effectiveness.
Value in health regional issues · 2026 · PMID 41707447
OBJECTIVES: This study systematically reviewed evidence on the cost and cost-effectiveness of breast cancer screening programs in China to support the development of structured, population-based screening initiatives and guide future economic evaluations. METHODS: A comprehensive search was conducted across Web of Science, CINAHL, PubMed, Embase, Medline, Google Scholar, PsycINFO, Cochrane, Scopus, and China National Knowledge Infrastructure for studies published up to June 2025. Eligible studies reported costs or …
Rank100.0
The Effect of Interpersonal Psychotherapy on Psychosocial Problems Among Breast Cancer Patients: A Systematic Review.
Seminars in oncology nursing · 2026 · PMID 41421895
OBJECTIVE: Breast cancer, one of the most prevalent cancers among women, not only results in significant physical changes but also causes considerable emotional distress and disruptions in social roles and relationships. While depression is the most commonly observed psychiatric disorder in cancer patients, there is a lack of sufficient research on the effectiveness, potential drug interactions, and side effects of antidepressants in this population. This gap underscores the increasing need for non-pharmacological …
Diagnosis And Screening380 records
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.3
Value of shear wave elastography in evaluating response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
The Journal of international medical research · 2026 · PMID 42690897
ObjectiveTo determine how well shear wave elastography performs as a diagnostic tool for determining the pathological response to neoadjuvant chemotherapy in breast cancer.MethodsThrough April 2025, a systematic search of PubMed, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, and SinoMed was used to perform a diagnostic meta-analysis. Included were studies of individuals with breast cancer receiving neoadjuvant chemotherapy with shear wave elastography evaluation. The diagnostic performance of …
Rank106.0
The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.
Social science & medicine (1982) · 2026 · PMID 42685390
BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in a…
Rank103.0
Ultrasound-based predictive models for response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
BMC cancer · 2026 · PMID 42277767
OBJECTIVE: This meta-analysis aimed to assess the diagnostic efficacy of ultrasound-based prediction models in evaluating the response to neoadjuvant chemotherapy (NAC) in breast cancer patients. METHODS: A systematic review was conducted using PubMed, Embase, and Web of Science from inception to May 2025. We focused on studies evaluating ultrasound-based prediction models for NAC response in breast cancer. Two investigators independently performed study selection and data extraction according to predefined eligibi…
Rank102.0
Effectiveness of self-management interventions in reducing cancer treatment-related cardiotoxicity in breast cancer survivors: A systematic review.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41953236
OBJECTIVE: To evaluate the effectiveness of self-management interventions in reducing cancer therapy-induced cardiotoxicity among breast cancer survivors. METHODS: Six English-language databases were searched for studies from January 2004 to November 2024. JBI appraisal tools and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework were applied to assess the methodological quality and certainty of the evidence. Meta-analysis and descriptive qualitative synthesis were applied. RES…
Rank100.3
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.
BJS open · 2026 · PMID 42551036
BACKGROUND: Axillary lymph node dissection (ALND) in breast cancer causes substantial arm morbidity and long-term functional impairment. Less extensive axillary surgery, such as targeted axillary dissection (TAD), significantly reduces this risk. Although omission of ALND is standard in clinically node-negative disease with limited sentinel node involvement, this is not the case for patients with clinically node-positive disease undergoing upfront surgery. The aim of the SENOMAC-ULTRA trial is to evaluate whether T…
Rank100.0
The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.
Annals of medicine · 2026 · PMID 41503829
BACKGROUND: Breast cancer (BC) remains a major global health concern, accounting for 11.7% of all cancer cases and ranking as the second leading cause of female cancer-related deaths worldwide. Increasing evidence highlights the interplay between gut microbiota (GM) dysbiosis and obesity-associated metabolic dysfunction in BC progression. This review aims to elucidate the role of GM in obese patients with BC. METHODS: A systematic literature search was conducted in PubMed and Web of Science databases for publicatio…
Rank100.0
Mapping the Prevalence of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Across Africa: A Systematic Review and Meta-Analysis.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42663196
BACKGROUND: BRCA1 and BRCA2 gene mutations are major contributors to hereditary breast and ovarian cancer syndrome (HBOC). While mutation prevalence has been well-characterized in high-income countries, African populations remain underrepresented in genomics cancer research. Accurate prevalence data are essential for informing targeted screening, counselling, and personalized treatment strategies across the continent. OBJECTIVE: To systematically assess the prevalence and geographic distribution of pathogenic BRCA1…
Rank100.0
Awareness is not enough: global evidence on breast cancer knowledge and self- screening practices among young women.
Journal of cancer policy · 2026 · PMID 42501835
BACKGROUND: Breast cancer remains a major global health concern and the leading cause of cancer-related mortality among women. The National Cancer Institute projects 30 million new cases and 15.3 million deaths worldwide by 2040. Early detection through screening significantly reduces mortality. Young women often perceive themselves as being at low risk, resulting in limited knowledge about breast cancer and low uptake of BSE. OBJECTIVE: This systematic literature review synthesises the existing literature to exami…
Rank100.0
Mapping interventions to increase uptake of breast and cervical cancer screening along the Intervention Ladder: a systematic review.
Health psychology review · 2026 · PMID 41637206
Timely breast and cervical cancer screening greatly reduce mortality, yet uptake remains sub-optimal, and intervention effectiveness varies across populations and settings. This systematic review applies the Intervention Ladder framework to classify interventions by their level of intrusiveness and assess their effectiveness in increasing uptake. Five databases (PubMed, Web of Science, EMBASE, Cochrane Library, SCOPUS) were searched for articles published from 2004 to October 2024, using terms related to cancer scr…
Rank100.0
Application and prospect of organoid technology in breast cancer.
Frontiers in immunology · 2024 · PMID 39253075
Breast cancer is the most common malignant tumor in women. Due to the high heterogeneity of breast cancer cells, traditional in vitro research models still have major limitations. Therefore, it is urgent to establish an experimental model that can accurately simulate the characteristics of human breast cancer. Breast cancer organoid technology emerged as the times required, that is, to construct tissue analogs with organ characteristics by using a patient's tumor tissue through 3D culture in vitro. Since the breast…
Rank99.4
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
Journal of the National Cancer Institute · 2026 · PMID 41934626
BACKGROUND: Responses to anti-HER2 therapy can vary based on estrogen receptor expression and HER2 gene amplification. This study assessed the magnitude of benefit by adding pertuzumab to trastuzumab and chemotherapy by estrogen receptor and HER2 levels in the APHINITY trial. METHODS: APHINITY (ClinicalTrials.gov identifier NCT01358877; BIG 4-11) was a randomized, double-blind, phase 3 trial comparing pertuzumab with placebo added to adjuvant trastuzumab and chemotherapy in 4804 patients with HER2-positive early br…
Rank98.1
Red Blood Cell Polyunsaturated Fatty Acids and Mortality Following Breast Cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024 · PMID 38656373
BACKGROUND: Intake of polyunsaturated fatty acids (PUFA) may affect mortality following breast cancer; however, epidemiological studies have relied on the self-reported assessment of PUFA intake. Herein, we examined the associations between red blood cell (RBC) PUFAs and mortality. METHODS: This nested case-control study included 1,104 women from the Women's Healthy Eating and Living study, a multistate randomized controlled trial. Cases (n = 290) comprised women who died from 1995 to 2006. Matched controls (n = 81…
Rank98.0
Breast cancer outcomes in low- and middle-income countries: Interactions of tumor biology, clinical care, and health-system capacity-A structured narrative review with an Indonesian case study.
Cancer treatment and research communications · 2026 · PMID 42679453
BACKGROUND: Breast cancer survival remains markedly unequal across countries, and the determinants of this gap extend beyond tumor biology. This structured narrative review examines how biological characteristics, stage at diagnosis, access to multimodality treatment, survivorship services, and health-system capacity interact in low- and middle-income countries (LMICs), with Indonesia developed as a country case study. METHODS: PubMed/MEDLINE and official World Health Organization (WHO), International Agency for Re…
Rank98.0
Mathematical Prediction Models for Sentinel Node Status in Early-Stage Breast Cancer: Protocol for a Systematic Review.
JMIR research protocols · 2026 · PMID 41871336
BACKGROUND: The status of the axilla remains a significant prognostic factor and influences adjuvant systemic and locoregional treatment choices in early-stage breast cancer (EBC). Sentinel node (SN) biopsy continues to be the preferred technique for establishing axillary nodal status in clinically node-negative EBC. A multivariable prediction model with adequate accuracy and generalizability has been explored as a potential alternative to SN. OBJECTIVE: This systematic review aims to evaluate the predictive perfor…
Rank97.6
Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.
Journal of the Egyptian National Cancer Institute · 2026 · PMID 42684555
BACKGROUND: Sentinel lymph node biopsy (SLNB) is standard for axillary staging in early breast cancer. While the combination of radioisotope and blue dye (e.g., patent blue V, PBV) remains the standard, it has limitations including logistics, variable identification rate (IR), and allergic potential. Indocyanine green (ICG) fluorescence is a promising alternative, but high-quality comparative evidence is needed. METHODS: This was a single-center, prospective, randomized controlled trial. Forty patients with early-s…
Rank97.2
Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment.
Clinical breast cancer · 2026 · PMID 42431149
BACKGROUND: Changes in patient-reported outcomes may be statistically significant, but not necessarily clinically significant. This study determined the minimal clinically important differences (MCIDs) in the Skin Symptom Assessment (SSA) questionnaire for the Mepitel film (MF) versus standard of care (SOC) randomized controlled trial for the prevention of radiation dermatitis (RD) in breast cancer patients. MCIDs are the smallest changes in patient-reported outcome measures (PROMs) that hold meaningful significanc…
Rank96.9
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42162664
BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 trial, 280 patients with high-risk TNBC received neoadjuvant carboplatin plus nab-paclitaxel (CT, n = 142) or the same regimen with atezolizumab (CT/A, n = 138). Tumor biopsies were collected …
Rank96.0
Effectiveness of Sentimag technology (Magseed and Magtrace localization) compared to traditional care for the management of early breast cancer: a systematic review protocol.
JBI evidence synthesis · 2026 · PMID 41536188
OBJECTIVE: This systematic review aims to evaluate the effectiveness, safety, and patient- and surgeon-related outcomes of the Sentimag platform (Magseed and Magtrace) as alternatives to traditional localization techniques in the surgical management of early breast cancer. INTRODUCTION: Magseed and Magtrace are magnetic localization technologies increasingly used to replace traditional wire-guided and radioisotope techniques for tumor and sentinel lymph node localization in breast-conserving surgery. While the tech…
Rank96.0
Experiences of implementation of personalised risk estimates for breast cancer in clinical practice: a systematic review and qualitative synthesis.
Journal of community genetics · 2026 · PMID 42405977
Breast cancer risk prediction tools are increasingly used in clinical practice to guide early detection, prevention, and shared decision-making. Unlike population-level screening, personalised risk estimates incorporate individual factors (family history, genetics, lifestyle, breast density), providing tailored assessments. These tools show promise for improving patient engagement and targeted prevention, but require effective implementation to ensure they enhance rather than complicate care. This review explores h…
Rank96.0
Time to diagnosis and treatment and breast cancer outcomes in young women: a systematic review protocol.
MethodsX · 2026 · PMID 42564769
Women under age 50 (young women) experience unique challenges when it comes to timely breast cancer diagnosis and treatment. Delays in diagnosis and treatment may contribute to disparities in survival outcomes, yet definitions and measurements of such delays often vary across studies. This protocol outlines the procedures for a systematic synthesis of evidence on the association between time to diagnosis and treatment and outcomes in women diagnosed with breast cancer under age 50. Primary observational research st…
Rank92.0
A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.
JAMA network open · 2026 · PMID 42658496
IMPORTANCE: Cascade genetic testing (CGT) is a key strategy for cancer prevention in families with hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS), yet uptake among at-risk relatives remains persistently low, particularly in medically underserved populations where structural and informational barriers limit access to genetic services. OBJECTIVE: To evaluate the feasibility and preliminary effects of IGNITE-TX (Identifying Individuals for Genetic Testing and Treatment), a scalable, bilin…
Rank92.0
Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42189890
PURPOSE: To independently validate that low endocrine transcriptional activity measured by the sensitivity to endocrine therapy (SETER/PR) index in hormone receptor-positive (HR+) breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. EXPERIMENTAL DESIGN: We conducted a blinded, prospective-retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FE…
Rank92.0
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42189888
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating the safety and efficacy of first-line treatment combinations with durvalumab (anti-PD-L1 antibody) for locally advanced, unresectable/metastatic TNBC (mTNBC; NCT03742102). In this study, we report results of 3 treatment arms. PATIENTS AND METHODS: Eligible female participants (≥18 years with untreate…
Rank92.0
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42048392
PURPOSE: Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle. PATIENTS AND METHODS: In part A (analytic validity phase), patients with stage II-III TNBC were randomized to FDG or FLT imaging. Baseli…
Evidence Syntheses107 records
Rank115.9
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026 · PMID 41342823
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rh…
Rank113.0
Beyond predictive performance: A systematic review and critical methodological appraisal of AI/ML and conventional modelling strategies in breast, colorectal, and pancreatic Cancer.
Artificial intelligence in medicine · 2026 · PMID 42641254
BACKGROUND: Predictive modelling for cancer risk, treatment-related complications, and survival is central to precision oncology. Conventional logistic regression (LR) and Cox proportional hazards (CoxPH) regression remain widely used but are limited when modelling nonlinear interactions, high-dimensional imaging features, and multimodal clinical-metabolic predictors. Artificial intelligence (AI) and machine learning (ML) methods offer expanded capability through automated feature extraction, ensemble learning, and…
Rank112.0
Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025 · PMID 39636577
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous…
Rank110.0
Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026 · PMID 42315709
BACKGROUND: Timely surgery is a key determinant of breast cancer outcomes; however, prior studies are inconsistent due to heterogeneous treatment pathways and inclusion of neoadjuvant therapy populations. The prognostic impact of delays to upfront surgery remains unclear. We evaluated the association between time from diagnosis to upfront surgery and survival in invasive breast cancer. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, and additional sources was conducted through April 25, 2025. Quantitative…
Rank110.0
[Integrated care for long-responder women with metastatic breast cancer: Expert opinion for long term management in spain].
Atencion primaria · 2026 · PMID 42296659
Metastatic breast cancer (mBC) has become a chronic disease for a growing number of women thanks to therapeutic advances, generating a new population of patients with prolonged response. This article, written by experts in oncology and primary care (PC) in Spain, offers practical recommendations for the comprehensive management of these patients. It addresses strategies to improve therapeutic compliance, the detection and management of toxicities, the early identification of signs of progression, and the management…
Rank110.0
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41671423
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and p…
Rank110.0
Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026 · PMID 41952250
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank109.9
Post-Diagnostic Diet and Breast Cancer Outcomes: A Comprehensive Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
Nutrients · 2026 · PMID 42654166
Background/Objectives: Diet is increasingly recognized as a modifiable factor in cancer survivorship; however, the impact of post-diagnostic dietary habits on breast cancer (BC) outcomes remains uncertain. This systematic review aimed to evaluate the association between diet after BC diagnosis and clinical outcomes and to provide an updated synthesis of the evidence, with particular emphasis on dietary assessment methods, methodological heterogeneity, and evidence gaps. Methods: We systematically reviewed randomize…
Rank109.7
Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.
Journal of neuro-oncology · 2026 · PMID 42550373
PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcomes, guidelines, and ongoing trials in TNBC-associated BM. METHODS: The review followed PRISMA guidance and was registered in the Open Science Framework (OSF.IO/6TDRF). MEDLINE, Scopus, Web of Science, DOAJ, and ClinicalTrials.gov we…
Rank109.3
Long-term hormone therapy for perimenopausal and postmenopausal women.
The Cochrane database of systematic reviews · 2026 · PMID 42695385
BACKGROUND: Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess the long-term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. SEARCH METHO…
Rank108.5
The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.
Breast cancer research and treatment · 2026 · PMID 42593586
PURPOSE: Adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve outcomes in hormone receptor-positive (HR+), HER2-negative early breast cancer, though trial results have been heterogeneous. Menopausal status and endocrine therapy backbone may contribute to variability in treatment effect. We performed a meta-analysis evaluating whether menopausal status influences the efficacy of adjuvant CDK 4/6 inhibition. METHODS: A systematic review of phase III randomized trials evaluating adjuvant CDK4/6i in HR+/HE…
Rank107.9
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Cancer control : journal of the Moffitt Cancer Center · 2026 · PMID 42619658
IntroductionAntibody-drug conjugates (ADCs) are now widely used in breast cancer across multiple disease subtypes. With increasing clinical use, treatment-related toxicities have become an important factor in therapeutic decision-making. However, comparative safety data among ADCs are limited because direct head-to-head trials are lacking.MethodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials evaluating ADCs in breast cancer, with the literature search updated thr…
Rank107.8
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · 2026 · PMID 42030172
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). METHODS: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC.…
Rank107.5
Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
PloS one · 2024 · PMID 38781221
INTRODUCTION: As of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug us…
Rank107.1
Efficacy, safety, and PD-L1-defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42656671
BACKGROUND: Neoadjuvant immune checkpoint inhibitors combined with chemotherapy improve pathological complete response in early-stage triple-negative breast cancer, but the consistency of benefit, role of PD-L1 expression, and immune-related toxicity remain clinically relevant. METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to June 30, 2026, for randomized trials comparing neoadjuvant immune checkpoint inhibitors plus chemotherapy with chemotherapy alone…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.8
Ginger in supportive therapy against side effects of oncological treatment: a systematic review.
BMC complementary medicine and therapies · 2026 · PMID 42613614
BACKGROUND: Oncology patients experience many side effects of their cancer treatment, which can affect their daily life. Phytotherapy is commonly used to reduce side effects or to support the treatment. Especially ginger plays a key role in the treatment of nausea and vomiting. The aim of this systematic review is to summarize the current scientific status of ginger in supportive therapy against side effects of oncological treatment. METHODS: In January 2025 a systematic search was conducted searching five electron…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.6
Comparative Effects of Various Delivery Methods of Cognitive Behavioral Therapy for Insomnia Among Patients With Cancers: Systematic Review and Network Meta-Analysis.
Psycho-oncology · 2026 · PMID 42670890
BACKGROUND: Insomnia affects 30%-60% of cancer survivors, with around 20% meeting criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment, but access is limited by cost and therapist availability, prompting exploration of alternative delivery modes, including digital interventions. PURPOSE: To systematically review and conduct a network meta-analysis (NMA) of the efficacy of different CBTi delivery methods for managing insomnia in cancer survivors. METHODS: The P…
Rank106.6
The Effects of Guided Imagery on Women's Health: A Systematic Review of Experimental Studies.
International journal of environmental research and public health · 2026 · PMID 42652381
BACKGROUND: Guided imagery (GI) is a mind-body intervention that uses sensory visualizations to promote relaxation and healing. While being utilized in various clinical settings, its specific cumulative impact on women's health across different life stages remains to be comprehensively synthesized. This systematic review aims to evaluate the effectiveness of GI on psychological and physiological outcomes in women's health, including gynecologic/breast cancer, pregnancy, childbirth, and menopause. METHODS: A systema…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.4
Erector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis.
World journal of surgical oncology · 2026 · PMID 42632896
BACKGROUND: Breast cancer surgeries remain the cornerstone of treatment for early-stage disease. Nonetheless, a substantial proportion of patients experience moderate-to-severe acute or chronic postoperative pain, adversely affecting quality of life and functional recovery. Regional anesthetic techniques have emerged as effective strategies for perioperative pain control. This study compares the erector spinae plane block (ESPB) and the thoracic paravertebral block (PVB) in breast cancer surgeries. METHODS: Four da…
Rank106.4
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · 2026 · PMID 41765743
INTRODUCTION: Fear of cancer recurrence (FCR) is among the most common and debilitating psychological issues affecting breast cancer survivors. With technological advances, e-health interventions have emerged as cost-effective tools to manage psychosocial challenges such as FCR. OBJECTIVES: This study aimed to systematically review and synthesize evidence from randomized controlled trials assessing the effectiveness of e-health interventions in reducing FCR among breast cancer survivors. METHODS: This systematic re…
Rank106.3
Value of shear wave elastography in evaluating response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
The Journal of international medical research · 2026 · PMID 42690897
ObjectiveTo determine how well shear wave elastography performs as a diagnostic tool for determining the pathological response to neoadjuvant chemotherapy in breast cancer.MethodsThrough April 2025, a systematic search of PubMed, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, and SinoMed was used to perform a diagnostic meta-analysis. Included were studies of individuals with breast cancer receiving neoadjuvant chemotherapy with shear wave elastography evaluation. The diagnostic performance of …
Landmark Evidence81 records
Rank115.9
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026 · PMID 41342823
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rh…
Rank112.0
Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025 · PMID 39636577
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous…
Rank110.0
Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026 · PMID 42315709
BACKGROUND: Timely surgery is a key determinant of breast cancer outcomes; however, prior studies are inconsistent due to heterogeneous treatment pathways and inclusion of neoadjuvant therapy populations. The prognostic impact of delays to upfront surgery remains unclear. We evaluated the association between time from diagnosis to upfront surgery and survival in invasive breast cancer. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, and additional sources was conducted through April 25, 2025. Quantitative…
Rank109.6
Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.
American journal of obstetrics and gynecology · 2025 · PMID 39521301
OBJECTIVE: To assess the risk of breast cancer recurrence, breast cancer-specific mortality, and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for genitourinary syndrome of menopause. DATA SOURCES: From the inception of each database to April 6th, 2024, a systematic literature search was conducted in Google Scholar, PubMed, EMBASE, CINAHL, NCBI, and Science Direct. A secondary search was conducted on September 26th, 2024 utilizing Google Scholar, PubMed, EMBASE, CINAHL, and Scienc…
Rank109.4
Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2024 · PMID 39270543
BACKGROUND: Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions. METHODS: A systematic search of literature from 2000 was performed to identify studies reporting BC …
Rank107.8
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · 2026 · PMID 42030172
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). METHODS: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC.…
Rank107.7
CADONOT: Comparing axillary dissection or not in breast cancer surgery.
Breast (Edinburgh, Scotland) · 2025 · PMID 40220731
INTRODUCTION: Sentinel lymph node biopsy (SLNB) is the gold standard for the axillary evaluation of clinically node-negative early breast cancer. The ACOSOG Z0011 study demonstrated the safety of omitting axillary dissection for limited SLNB disease, with other trials confirming SLNB alone or with axillary radiotherapy (AR) as non-inferior. METHODS: We followed PRISMA guidelines and registered at PROSPERO. Using Medline, Embase, and Cochrane, we reviewed randomized controlled trials (2010-2024). Outcomes, including…
Rank107.5
Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
PloS one · 2024 · PMID 38781221
INTRODUCTION: As of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug us…
Rank107.0
Migraine and Risk of Breast Cancer: A Systematic Review and Meta-analysis.
Clinical breast cancer · 2023 · PMID 36624014
Migraine and breast cancer are 2 prevalent diseases with high morbidity and mortality rates world-wide. There have been inconsistent reports regarding the association between migraine and risk of breast cancer. This systematic review and meta-analysis aimed to assess the risk of breast cancer in patients with migraine. By December, 1, 2022, we searched PubMed, Web of Science, Scopus, and Cochrane Library databases. Odds ratio (OR), hazard ratio (HR), and 95% confidence intervals (CIs) were extracted or assessed to …
Rank106.6
Comparative Effects of Various Delivery Methods of Cognitive Behavioral Therapy for Insomnia Among Patients With Cancers: Systematic Review and Network Meta-Analysis.
Psycho-oncology · 2026 · PMID 42670890
BACKGROUND: Insomnia affects 30%-60% of cancer survivors, with around 20% meeting criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment, but access is limited by cost and therapist availability, prompting exploration of alternative delivery modes, including digital interventions. PURPOSE: To systematically review and conduct a network meta-analysis (NMA) of the efficacy of different CBTi delivery methods for managing insomnia in cancer survivors. METHODS: The P…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.5
Gut microbiota and breast cancer: systematic review and meta-analysis.
Breast cancer (Tokyo, Japan) · 2025 · PMID 39652259
BACKGROUND: The gastrointestinal microbiota can modulate systemic estrogens, potentially influencing estrogen-induced breast neoplasia development. This study aimed to assess alterations in the gut microbiota in breast cancer patients. METHODS: A search strategy was developed using the terms: "Microbiota," "Gastrointestinal Microbiome," "Breast Cancer," and synonyms. Ten observational studies were included. RESULTS: The total sample was 1730 women (929 cases and 801 controls). The meta-analysis of alpha diversity, …
Rank106.4
Locoregional therapy containing surgery in metastatic breast cancer: Systematic review and meta-analysis.
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland · 2024 · PMID 37858431
INTRODUCTION: The role of locoregional therapy (LRT) containing surgery and systematic therapy in metastatic breast cancer patients remains controversial. This study investigated the effect of LRT in patients who were initially diagnosed with metastatic breast cancer (MBC) on overall survival (OS), locoregional progression-free survival (PFS), and distant systemic PFS. METHODS: The related keywords were searched in MEDLINE/PubMed, SCOPUS, and Web of Science databases up to August 15th, 2022. Hazard ratios (HR) with…
Rank106.4
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · 2026 · PMID 41765743
INTRODUCTION: Fear of cancer recurrence (FCR) is among the most common and debilitating psychological issues affecting breast cancer survivors. With technological advances, e-health interventions have emerged as cost-effective tools to manage psychosocial challenges such as FCR. OBJECTIVES: This study aimed to systematically review and synthesize evidence from randomized controlled trials assessing the effectiveness of e-health interventions in reducing FCR among breast cancer survivors. METHODS: This systematic re…
Rank106.3
Chatbots for breast cancer education: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · PMID 39730943
BACKGROUND: Effective education and awareness regarding breast cancer are critical. Traditional educational methods often fail to meet the diverse information needs of patients. Patients should be provided with tailored, accessible information to improve their retention and understanding of disease-related information. PURPOSE: This systematic review and meta-analysis evaluated the effectiveness of chatbots for providing breast cancer education. By examining patient satisfaction with and the usability and efficacy …
Rank106.2
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Cancer treatment reviews · 2022 · PMID 36202026
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overal…
Rank106.0
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · 2026 · PMID 42289089
OBJECTIVE: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM). STUDY SELECTION: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidenc…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank104.8
Psychoeducation for breast cancer: A systematic review and meta-analysis.
Breast (Edinburgh, Scotland) · 2022 · PMID 35121502
BACKGROUND: Psychoeducation has emerged as an intervention for women with breast cancer (BC). This meta-analysis evaluated the effectiveness of psychoeducation on adherence to diagnostic procedures and medical treatment, anxiety, depression, quality of life (QoL), and BC knowledge among patients with BC symptoms or diagnosis and BC survivors. METHODS: A systematic literature search (in PubMed, Embase, PsycINFO and Cochrane) for randomised controlled trials (RCTs) comparing the effects of psychoeducation to control …
Rank104.2
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 · PMID 41396594
IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive da…
Rank103.7
The Association Between Meningioma and Breast Cancer: A Systematic Review and Meta-analysis.
JAMA network open · 2023 · PMID 37326990
IMPORTANCE: A potential relationship between meningioma and breast cancer was suggested 70 years ago. However, to date, no conclusive evidence is available on this topic. OBJECTIVE: To provide a comprehensive review of the literature on the association of meningioma with breast cancer, supported by a meta-analysis. DATA SOURCES: A systematic PubMed search was performed up to April 2023 to identify articles on the association of meningioma with breast cancer. The following key words were used strategically: meningio…
Rank103.5
Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Journal of cancer research and therapeutics · 2023 · PMID 38376268
Tumor budding is gaining importance as a prognostic factor in various carcinomas due to its association with epithelial-mesenchymal transition (EMT) and hence clinical outcome. Reporting tumor budding in breast cancer lacks homogeneity. We aim to systematically review the existing literature and conduct a meta-analysis to assess the prognostic implication of tumor budding in breast carcinoma. A systematic search was performed to identify studies that compared different prognostic variables between high- and low-gra…
Rank103.4
Manual Lymphatic Drainage for Breast Cancer-related Lymphedema: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Clinical breast cancer · 2022 · PMID 35370085
BACKGROUND: The purpose of this systematic review was to meta-analyze the effectiveness of manual lymphatic drainage (MLD) in breast cancer-related lymphedema (BCRL) patients. METHODS: The following databases: the Cochrane Library, the Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Web of Science, ClinicalTrials.gov were systematically searched. All English publications before April 2021 have been retrieved without any restrictions of countries, time, or article type. We included randomized control…
Rank103.4
Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis.
Critical reviews in oncology/hematology · 2023 · PMID 36535489
Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase inhibitor therapies in patients with breast cancer. A systematic review using network meta-analysis (NMA) was conducted to examine the clinical effectiveness of multiple therapies and rank probabilities for the management of AIA. Randomized controlled trials (RCTs) assessing treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer were searched from inception to October 2021. The main N…
Rank102.6
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Expert opinion on drug safety · 2026 · PMID 39960238
BACKGROUND: Cell-cycle protein-dependent kinase 4 and 6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) are widely used in patients with early and advanced breast cancer (BC). CDK4/6is also lead to numerous side effects. This study aims to elucidate the relationship between CDK4/6is and hepatotoxicities. RESEARCH DESIGN AND METHODS: As of 31 March 2024, we conducted a systematic search of PubMed, Embase, and the Cochrane Library databases, as well as several oncology conference proceedings. We incl…
Most Effective Evidence Supported Treatments142 records
Rank112.0
Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Genetics in medicine : official journal of the American College of Medical Genetics · 2025 · PMID 39636577
PURPOSE: ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer. Resources for managing ATM heterozygotes in clinical practice are limited. METHODS: An international workgroup developed a clinical practice resource to guide management of ATM heterozygotes using peer-reviewed publications and expert opinion. RESULTS: Although ATM is a moderate (intermediate) penetrance gene, cancer risks may be considered as a continuous…
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank110.0
Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026 · PMID 42315709
BACKGROUND: Timely surgery is a key determinant of breast cancer outcomes; however, prior studies are inconsistent due to heterogeneous treatment pathways and inclusion of neoadjuvant therapy populations. The prognostic impact of delays to upfront surgery remains unclear. We evaluated the association between time from diagnosis to upfront surgery and survival in invasive breast cancer. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, and additional sources was conducted through April 25, 2025. Quantitative…
Rank109.7
Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.
Journal of neuro-oncology · 2026 · PMID 42550373
PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcomes, guidelines, and ongoing trials in TNBC-associated BM. METHODS: The review followed PRISMA guidance and was registered in the Open Science Framework (OSF.IO/6TDRF). MEDLINE, Scopus, Web of Science, DOAJ, and ClinicalTrials.gov we…
Rank107.9
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Cancer control : journal of the Moffitt Cancer Center · 2026 · PMID 42619658
IntroductionAntibody-drug conjugates (ADCs) are now widely used in breast cancer across multiple disease subtypes. With increasing clinical use, treatment-related toxicities have become an important factor in therapeutic decision-making. However, comparative safety data among ADCs are limited because direct head-to-head trials are lacking.MethodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials evaluating ADCs in breast cancer, with the literature search updated thr…
Rank107.8
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · 2026 · PMID 42030172
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). METHODS: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC.…
Rank107.5
Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
PloS one · 2024 · PMID 38781221
INTRODUCTION: As of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug us…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.6
Comparative Effects of Various Delivery Methods of Cognitive Behavioral Therapy for Insomnia Among Patients With Cancers: Systematic Review and Network Meta-Analysis.
Psycho-oncology · 2026 · PMID 42670890
BACKGROUND: Insomnia affects 30%-60% of cancer survivors, with around 20% meeting criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment, but access is limited by cost and therapist availability, prompting exploration of alternative delivery modes, including digital interventions. PURPOSE: To systematically review and conduct a network meta-analysis (NMA) of the efficacy of different CBTi delivery methods for managing insomnia in cancer survivors. METHODS: The P…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.4
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · 2026 · PMID 41765743
INTRODUCTION: Fear of cancer recurrence (FCR) is among the most common and debilitating psychological issues affecting breast cancer survivors. With technological advances, e-health interventions have emerged as cost-effective tools to manage psychosocial challenges such as FCR. OBJECTIVES: This study aimed to systematically review and synthesize evidence from randomized controlled trials assessing the effectiveness of e-health interventions in reducing FCR among breast cancer survivors. METHODS: This systematic re…
Rank106.4
Erector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis.
World journal of surgical oncology · 2026 · PMID 42632896
BACKGROUND: Breast cancer surgeries remain the cornerstone of treatment for early-stage disease. Nonetheless, a substantial proportion of patients experience moderate-to-severe acute or chronic postoperative pain, adversely affecting quality of life and functional recovery. Regional anesthetic techniques have emerged as effective strategies for perioperative pain control. This study compares the erector spinae plane block (ESPB) and the thoracic paravertebral block (PVB) in breast cancer surgeries. METHODS: Four da…
Rank106.3
Value of shear wave elastography in evaluating response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
The Journal of international medical research · 2026 · PMID 42690897
ObjectiveTo determine how well shear wave elastography performs as a diagnostic tool for determining the pathological response to neoadjuvant chemotherapy in breast cancer.MethodsThrough April 2025, a systematic search of PubMed, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, and SinoMed was used to perform a diagnostic meta-analysis. Included were studies of individuals with breast cancer receiving neoadjuvant chemotherapy with shear wave elastography evaluation. The diagnostic performance of …
Rank106.0
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · 2026 · PMID 42289089
OBJECTIVE: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM). STUDY SELECTION: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidenc…
Rank105.8
Emotional freedom techniques for cancer-related sleep disturbance and associated symptoms: A systematic review and meta-analysis.
Complementary therapies in medicine · 2026 · PMID 42595020
BACKGROUND: Cancer patients frequently experience a debilitating and interconnected symptom cluster comprising pain, fatigue, and sleep disturbance (P-F-S), which negatively impacts their quality of life and treatment outcomes. Emotional Freedom Techniques (EFT), a mind-body intervention combining cognitive exposure with acupoint stimulation, has shown potential for addressing psychological distress, yet its effectiveness on this specific physiological symptom cluster remains underexplored. OBJECTIVES: This systema…
Rank105.7
Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.
Anales del sistema sanitario de Navarra · 2026 · PMID 42657993
Background Hormone receptor-positive breast cancer is treated with endocrine therapies to reduce recurrence and mortality. These therapies have side effects that negatively affect quality of life (QoL). We aim to synthesize the available evidence on the impact of non-pharmacological interventions on QoL and its specific domains (physical, psychological, social, and spiritual) in female breast cancer survivors undergoing endocrine therapies. Methods A systematic review following the Cochrane and PRISMA guidelines wa…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank105.2
Digital Health Interventions and Psychosocial Outcomes in Women With Breast Cancer: Systematic Review.
JMIR cancer · 2026 · PMID 42627958
BACKGROUND: Breast cancer and its treatment can negatively affect women's quality of life (QoL), including physical, psychological, and social well-being. Digital health interventions have been increasingly used to provide supportive care, but their effectiveness on QoL and related psychosocial outcomes remains unclear. OBJECTIVE: This review aimed to evaluate the effectiveness of digital health interventions on QoL in women with breast cancer and to assess their effects on anxiety, depression, and self-efficacy. M…
Rank105.1
Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42690445
PURPOSE: Cancer therapy-related cardiac dysfunction (CTRCD) is a significant concern for breast cancer patients undergoing anthracycline-based chemotherapy. Although exercise has been proposed as a cardioprotective strategy, existing reviews have largely examined heterogeneous cancer populations receiving varied treatments, leaving a gap in the evidence base focused exclusively on anthracycline-induced CTRCD. This systematic review and meta-analysis aimed to address that gap by evaluating the effects of long-term e…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank104.3
Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.
International journal of clinical pharmacology and therapeutics · 2026 · PMID 42290268
OBJECTIVE: Through a network meta-analysis, this study aimed to systematically evaluate the efficacy and safety of bisphosphonates in reducing skeletal-related events in patients with bone metastases from breast cancer, providing clinical guidance for treatment selection. MATERIALS AND METHODS: Randomized controlled trials (RCTs) on bisphosphonate therapy for bone metastases in breast cancer were retrieved from PubMed, Cochrane, and Embase databases from inception to January 2025. Statistical analyses were performe…
Rank104.2
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 · PMID 41396594
IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive da…
Rank103.4
Autophagy potential of polyphenols in breast carcinoma: A systematic review.
Pathology, research and practice · 2026 · PMID 42475944
PURPOSE: This systematic review presents data on the role of polyphenols in autophagy in breast cancer. METHODS: All research on polyphenol-induced autophagy in breast carcinoma was comprehensively searched in the electronic PubMed, Web of Science, Scopus, EMBASE, and Google Scholar databases up to January 1, 2025. The keywords were searched using the controlled vocabulary (Medical Subject Headings [MeSH]) with the terms Breast Cancer, polyphenols, and Autophagy. Following the guidelines of the Preferred Reporting …
New Research Last 24 Months487 records
Rank110.0
Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026 · PMID 42315709
BACKGROUND: Timely surgery is a key determinant of breast cancer outcomes; however, prior studies are inconsistent due to heterogeneous treatment pathways and inclusion of neoadjuvant therapy populations. The prognostic impact of delays to upfront surgery remains unclear. We evaluated the association between time from diagnosis to upfront surgery and survival in invasive breast cancer. METHODS: A systematic search of MEDLINE, Embase, CENTRAL, and additional sources was conducted through April 25, 2025. Quantitative…
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank107.8
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · 2026 · PMID 42030172
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). METHODS: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC.…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.6
Comparative Effects of Various Delivery Methods of Cognitive Behavioral Therapy for Insomnia Among Patients With Cancers: Systematic Review and Network Meta-Analysis.
Psycho-oncology · 2026 · PMID 42670890
BACKGROUND: Insomnia affects 30%-60% of cancer survivors, with around 20% meeting criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment, but access is limited by cost and therapist availability, prompting exploration of alternative delivery modes, including digital interventions. PURPOSE: To systematically review and conduct a network meta-analysis (NMA) of the efficacy of different CBTi delivery methods for managing insomnia in cancer survivors. METHODS: The P…
Rank106.4
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · 2026 · PMID 41765743
INTRODUCTION: Fear of cancer recurrence (FCR) is among the most common and debilitating psychological issues affecting breast cancer survivors. With technological advances, e-health interventions have emerged as cost-effective tools to manage psychosocial challenges such as FCR. OBJECTIVES: This study aimed to systematically review and synthesize evidence from randomized controlled trials assessing the effectiveness of e-health interventions in reducing FCR among breast cancer survivors. METHODS: This systematic re…
Rank106.3
Value of shear wave elastography in evaluating response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
The Journal of international medical research · 2026 · PMID 42690897
ObjectiveTo determine how well shear wave elastography performs as a diagnostic tool for determining the pathological response to neoadjuvant chemotherapy in breast cancer.MethodsThrough April 2025, a systematic search of PubMed, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, and SinoMed was used to perform a diagnostic meta-analysis. Included were studies of individuals with breast cancer receiving neoadjuvant chemotherapy with shear wave elastography evaluation. The diagnostic performance of …
Rank106.0
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · 2026 · PMID 42289089
OBJECTIVE: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM). STUDY SELECTION: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidenc…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank105.1
Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42690445
PURPOSE: Cancer therapy-related cardiac dysfunction (CTRCD) is a significant concern for breast cancer patients undergoing anthracycline-based chemotherapy. Although exercise has been proposed as a cardioprotective strategy, existing reviews have largely examined heterogeneous cancer populations receiving varied treatments, leaving a gap in the evidence base focused exclusively on anthracycline-induced CTRCD. This systematic review and meta-analysis aimed to address that gap by evaluating the effects of long-term e…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank104.2
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 · PMID 41396594
IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive da…
Rank103.8
MIF -173 G>C polymorphism as a context-dependent modifier of solid cancer risk: A meta-analysis.
Cancer treatment and research communications · 2026 · PMID 42673731
BACKGROUND: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine implicated in immune regulation and cancer development. A functional promoter polymorphism in MIF (-173 G>C; rs755622) has been investigated for its association with cancer susceptibility, but results remain inconsistent across populations and tumor types. METHODS: To evaluate the association between the MIF -173 G>C polymorphism and susceptibility to solid cancers, the PubMed, Scopus, and ProQuest databases were searched for ca…
Rank102.6
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Expert opinion on drug safety · 2026 · PMID 39960238
BACKGROUND: Cell-cycle protein-dependent kinase 4 and 6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) are widely used in patients with early and advanced breast cancer (BC). CDK4/6is also lead to numerous side effects. This study aims to elucidate the relationship between CDK4/6is and hepatotoxicities. RESEARCH DESIGN AND METHODS: As of 31 March 2024, we conducted a systematic search of PubMed, Embase, and the Cochrane Library databases, as well as several oncology conference proceedings. We incl…
Rank102.0
Uptake of breast cancer risk-management strategies among unaffected BRCA 1/2 carriers: a systematic review of international evidence.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42442074
BACKGROUND: Women carrying BRCA1/BRCA2 pathogenic variants face a substantially increased risk of breast cancer and may choose between risk-reducing mastectomy (RRM) or intensive surveillance. This systematic review aimed to synthesise the available evidence on the uptake of breast cancer risk management strategies among unaffected BRCA1/2 carriers. METHODS: A systematic review was conducted in accordance with PRISMA guidelines. Four electronic databases (PubMed, Scopus, Web of Science, ASSIA) and grey literature s…
Rank101.4
Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42666138
OBJECTIVE: To systematically review the efficacy of chemotherapy combined with targeted therapy in the handling of advanced triple-negative breast cancer (TNBC). METHODS: A thorough literature search was carried out across several databases, including PubMed, EMBASE, ScienceDirect, and Chinese medical databases, for case-control trials on TNBC patients treated with chemotherapy combined with targeted therapy versus chemotherapy alone. Two separate researchers extracted the data, and the risk of bias was assessed us…
Rank100.0
Current evidence on the prospective predictors and trajectories of posttraumatic growth and depreciation in adult women with breast cancer: a systematic review of longitudinal studies.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42576029
PURPOSE: Breast cancer remains a global health concern, with post-traumatic psychological changes, both positive and negative, during treatment and survivorship. This systematic review aimed to examine the prospective predictors of Posttraumatic Growth (PTG) and Posttraumatic Depreciation (PTD), as well as their temporal dynamics in women diagnosed with breast cancer. METHODS: PubMed, Scopus, CINAHL, and PsycINFO were systematically searched on 31st January 2025, using a combination of terms and Boolean operators, …
Rank100.0
Mapping interventions to increase uptake of breast and cervical cancer screening along the Intervention Ladder: a systematic review.
Health psychology review · 2026 · PMID 41637206
Timely breast and cervical cancer screening greatly reduce mortality, yet uptake remains sub-optimal, and intervention effectiveness varies across populations and settings. This systematic review applies the Intervention Ladder framework to classify interventions by their level of intrusiveness and assess their effectiveness in increasing uptake. Five databases (PubMed, Web of Science, EMBASE, Cochrane Library, SCOPUS) were searched for articles published from 2004 to October 2024, using terms related to cancer scr…
Rank100.0
Sexual intimacy after breast cancer: A systematic review of qualitative studies on women's and partners' experiences in dating and romantic relationships.
Body image · 2026 · PMID 42603448
Body changes related to breast cancer treatment are associated with body image concerns and sexual and intimacy difficulties that adversely affect quality of life, yet remain frequently unaddressed by healthcare professionals. Although existing reviews have examined these challenges among women with breast cancer, none have synthesised qualitative evidence incorporating partners' perspectives or spanning different intimate partnerships, including dating and emerging relationships. This systematic review aimed to sy…
Rank100.0
Breast cancer incidence and mortality in population studies of radiation exposure: systematic review and meta-analysis.
British journal of cancer · 2026 · PMID 42303831
BACKGROUND: While breast cancer risk from high-dose ionising radiation is known, uncertainties remain about risks at lower doses and risk-modifying factors. We conducted a systematic review and meta-analysis of publications on radiation-associated risk of breast cancer in women. METHODS: We included studies published in 2005-2022 that assessed breast cancer incidence or mortality in women exposed to ionising radiation. Risk of bias was evaluated. Random-effects meta-analyses estimated excess relative risks per gray…
Rank100.0
Awareness is not enough: global evidence on breast cancer knowledge and self- screening practices among young women.
Journal of cancer policy · 2026 · PMID 42501835
BACKGROUND: Breast cancer remains a major global health concern and the leading cause of cancer-related mortality among women. The National Cancer Institute projects 30 million new cases and 15.3 million deaths worldwide by 2040. Early detection through screening significantly reduces mortality. Young women often perceive themselves as being at low risk, resulting in limited knowledge about breast cancer and low uptake of BSE. OBJECTIVE: This systematic literature review synthesises the existing literature to exami…
Rank100.0
Effects of exercise interventions on sleep quality in breast cancer survivors: a systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42676424
BACKGROUND: The probability of postoperative sleep disturbances in breast cancer survivors exceeds 60%. Poor sleep quality substantially undermines quality of life, exacerbates fatigue, and impairs postoperative recovery. OBJECTIVE: To systematically review the effects of exercise interventions on sleep quality in breast cancer survivors and explore whether effect estimates vary according to exercise intervention characteristics. METHODS: We searched PubMed, Web of Science, Embase, and the Cochrane Library from inc…
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41808362
BACKGROUND: Menopausal hormone therapy (MHT) is widely prescribed for alleviating menopausal symptoms. Prior studies have mainly focused on individual hormone therapy formulations. This meta-analysis comprehensively synthesized evidence across various regimens to systematically evaluate the association between MHT and breast cancer risk. MATERIALS AND METHODS: We systematically searched CNKI, Wanfang, PubMed, and Web of Science from inception through August 2024. Eligible studies examining breast cancer risk follow…
Rank99.1
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.
International journal of cancer · 2026 · PMID 42056728
Chemotherapy-induced nausea and vomiting (CINV) remains an important side effect despite new antiemetic drugs. This study tried to understand the occurrence of CINV in patients receiving two different chemotherapy regimens. As part of the randomized controlled clinical trial SUCCESS C (NCT00847444), 1582 of the 3463 patients completed CINV diaries. Patients were randomized to receive either chemotherapy with FEC (5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel) or TC (docetaxel, cyclophosphamide)…
Preclinical Research124 records
Rank115.9
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026 · PMID 41342823
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rh…
Rank103.4
Autophagy potential of polyphenols in breast carcinoma: A systematic review.
Pathology, research and practice · 2026 · PMID 42475944
PURPOSE: This systematic review presents data on the role of polyphenols in autophagy in breast cancer. METHODS: All research on polyphenol-induced autophagy in breast carcinoma was comprehensively searched in the electronic PubMed, Web of Science, Scopus, EMBASE, and Google Scholar databases up to January 1, 2025. The keywords were searched using the controlled vocabulary (Medical Subject Headings [MeSH]) with the terms Breast Cancer, polyphenols, and Autophagy. Following the guidelines of the Preferred Reporting …
Rank100.0
Application and prospect of organoid technology in breast cancer.
Frontiers in immunology · 2024 · PMID 39253075
Breast cancer is the most common malignant tumor in women. Due to the high heterogeneity of breast cancer cells, traditional in vitro research models still have major limitations. Therefore, it is urgent to establish an experimental model that can accurately simulate the characteristics of human breast cancer. Breast cancer organoid technology emerged as the times required, that is, to construct tissue analogs with organ characteristics by using a patient's tumor tissue through 3D culture in vitro. Since the breast…
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.
Annals of medicine · 2026 · PMID 41503829
BACKGROUND: Breast cancer (BC) remains a major global health concern, accounting for 11.7% of all cancer cases and ranking as the second leading cause of female cancer-related deaths worldwide. Increasing evidence highlights the interplay between gut microbiota (GM) dysbiosis and obesity-associated metabolic dysfunction in BC progression. This review aims to elucidate the role of GM in obese patients with BC. METHODS: A systematic literature search was conducted in PubMed and Web of Science databases for publicatio…
Rank92.0
Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
Cell reports. Medicine · 2026 · PMID 42561946
Poor therapeutic response in subsets of breast cancer (BC) patients poses an ongoing challenge. Here, we present a biomarker-guided characterization of 40 patient-derived BC organoids, with the aim of modeling resistant disease with greater fidelity and developing an in vitro system grounded in clinical data for testing alternative treatment strategies. We utilize patient data from the I-SPY2 clinical trial (NCT01042379) to develop predictive models of response to a range of therapies, using only organoid-detectabl…
Rank88.2
Efficacy and Safety of Viscum album L. in Patients With Triple-Negative Breast Cancer Receiving Immune Checkpoint Inhibitors: A Protocol for an Open-Label Randomized Clinical Trial.
Integrative cancer therapies · 2026 · PMID 42657864
Although pembrolizumab has shown clinical benefit in triple-negative breast cancer (TNBC), effective long-term responses remain limited. Viscum album (mistletoe extracts, VA) may have immunomodulatory, pro-apoptotic, and immune-stimulating effects in preclinical and clinical studies. This trial was designed to evaluate the immunologic effects and safety of combining pembrolizumab with VA in the adjuvant setting. This open-label, randomized, clinical trial will include 40 adults (≥19 years) with histologically confi…
Rank83.0
Estrogen Signaling During Abrupt Involution and Long-Term Metabolic Signature Similar to Estrogen Receptor-Negative Breast Cancer.
International journal of molecular sciences · 2026 · PMID 41752087
Epidemiological data link a lack of breastfeeding with an increased risk of breast cancer. Breast tissue remodels after pregnancy through involution. Long-term breastfeeding results in gradual involution (GI), and a lack of breastfeeding leads to abrupt involution (AI). AI causes increased mammary gland estrogen signaling, causing adipocyte redifferentiation through neutrophil infiltration. Adipocyte differences and metabolic implications of involution have not been explored between AI and GI. As breast cancer is c…
Rank80.0
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Cancer research · 2025 · PMID 39777474
Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening in ER+ breast cancer cells, we identified a survival mechanism involving metabolic reprogramming with re…
Rank72.6
Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42142622
BACKGROUND: TQB2102 is a next-generation biparatopic antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) extracellular domain 2 (ECD2) and ECD4 epitopes that is conjugated to a topoisomerase I inhibitor via an enzyme-cleavable linker. This study evaluated the safety, efficacy, and pharmacokinetics of TQB2102 in patients with advanced solid tumors. PATIENTS AND METHODS: In this phase I, multicenter, first-in-human trial, patients with advanced solid tumors were recruited from 12 centers…
Rank50.2
Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer.
Nature communications · 2026 · PMID 42675068
Metastasis remains the leading cause of cancer-related mortality, yet predicting future metastasis is a major clinical challenge due to the lack of validated biomarkers and effective assessment methods. Here, we present EmitGCL, a deep-learning framework that accurately predicts future metastasis and its corresponding biomarkers. Based on a comprehensive benchmarking comparison, EmitGCL outperforms other computational tools across six cancer types from seven cohorts of patients with superior sensitivity and specifi…
Rank47.3
Belt electrode-skeletal muscle electrical stimulation-induced attenuation of aromatase inhibitor-induced bone loss in ovariectomized rats.
Bone · 2026 · PMID 42259425
Cancer treatment-induced bone loss (CTIBL) is a clinically significant adverse effect of endocrine therapy in hormone-related cancers, including breast cancer. Pharmacological interventions, including antiresorptive agents, are widely used; however, few nonpharmacological interventions ensure preservation of bone health without imposing excessive physical burden. We investigated the preventive effects of belt electrode-skeletal muscle electrical stimulation (B-SES) on aromatase inhibitor (AI)-induced bone loss in a…
Rank45.0
Dose-dependent neurotoxic effects of anastrozole via disrupting NLRP3 inflammasome and α-synuclein pathways.
Tissue & cell · 2026 · PMID 42139902
Anastrozole (ANZ) is a commonly used aromatase inhibitor in the treatment of hormone-dependent breast cancer. Despite its toxicity profile reported in different studies, the neurotoxic effects against this drug have not been explored yet. The present study was aimed at investigating the neurotoxic effects of ANZ in Sprague Dawley rats using comprehensive biochemical, molecular and histopathological analysis. Rats were divided into control and ANZ treated (0.1, 0.2 and 0.5 mg/ kg) doses. It was found that ANZ intoxi…
Rank45.0
Space Jam-Ming: Generating Interstitial Space Using Fragmented Granular GelMA to Investigate Novel Paradigms of Cancer Metastasis.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · PMID 42669624
The tumor microenvironment undergoes extensive remodeling during cancer progression, resulting in increased collagen, altered tissue mechanics, and the formation of collagen tracks that permit migration. However, how the extracellular matrix (ECM) regulates cellular plasticity remains less known. Cellular plasticity is essential for successful metastasis, as cells undergo epithelial-to-mesenchymal transition and adherent-to-suspension transition (AST). Studies have begun to use 3D photo-crosslinkable hydrogels, but…
Rank45.0
Characterization of microvascular remodeling in metastatic sentinel lymph nodes via skeletonization framework generated by ultrasound localization microscopy.
Ultrasonics · 2026 · PMID 42090859
Lymphatic spread to the sentinel lymph node (SLN) represents the primary pathway for early-stage breast cancer metastasis. Given that metastatic progression is fundamentally driven by pathological angiogenesis, high-resolution imaging and quantification of SLN microvasculature are critical for assessing tumor spread. In this study, we applied ultrasound localization microscopy (ULM) to a rabbit VX2 breast tumor model and developed a skeletonization-based analytical framework to quantify lymphatic microvascular morp…
Rank45.0
Detection of malignancies in mice using TXRF analysis and reaction-based optical fingerprinting of blood plasma.
Analytica chimica acta · 2026 · PMID 42508915
This study explores the potential of reaction-based optical fingerprinting and total X-ray fluorescence (TXRF) elemental analysis, both separately and in combination, as a rapid and inexpensive approach to preliminary cancer diagnostics. Plasma samples from BALB/c mice with transplanted mammary carcinoma (EMT-6) and BDF1 mice with Lewis lung carcinoma (LLC) or B16 melanoma were analyzed. The optical fingerprinting method relies on differences in the oxidation rate of a carbocyanine dye in the presence of blood plas…
Rank45.0
Green synthesis of copper hydroxide nanorods using Solanum pubescens leaf extracts: a promising approach for antimicrobial, antioxidant, and anticancer applications.
3 Biotech · 2025 · PMID 40771587
UNLABELLED: Copper hydroxide nanorods (Cu(OH)₂ NRs) were successfully produced using ethanolic leaf extracts of Solanum pubescens utilizing a green synthesis technique. UV-Vis, FTIR, XRD, and SEM-EDX analysis revealed the development of orthorhombic, rod-shaped nanoparticles with an average size of ~ 50 nm. Cu(OH)₂ NRs showed significant antibacterial activity, with inhibition zones ranging from 8.55 ± 0.59 mm to 9.80 ± 0.68 mm against bacterial strains like S. aureus and K. pneumoniae, and 6.20 ± 0.43 mm to 7.90 ±…
Rank45.0
An exploratory pre-clinical study of the combination of hyperthermia and checkpoint inhibitors.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42517178
BACKGROUND AND PURPOSE: This was a pre-clinical study designed to investigate the potential of combining hyperthermia with checkpoint inhibitors. MATERIAL AND METHODS: C3H mammary carcinomas, grown in the right rear foot of CDF1 mice, were treated when tumors reached 200 mm3. Hyperthermia (39.5-42.5 °C for 30-120 min) was applied following immersion of the tumor bearing leg into a circulating water bath. The checkpoint inhibitors were anti-CTLA-4/PD-1/PD-L1 antibodies injected intraperitoneally (4 x 10 mg/kg). Tumo…
Rank45.0
Lifelong dietary interventions selectively reverse age-associated circulating microRNA upregulation in a time-dependent manner in female MMTV-TGF-α mice.
Biogerontology · 2026 · PMID 42658308
Breast cancer is among the leading causes of cancer mortality worldwide, with aging as a major risk factor. Caloric restriction (CR) is a well-established non-pharmaceutical intervention that extends healthspan and delays tumorigenesis, yet the systemic molecular mechanisms remain elusive. Both chronic and intermittent CR influence metabolic homeostasis, but their long-term effects on circulating miRNAs in breast cancer predisposition are unclear. Here, we examined how chronic and intermittent CR and subsequent ref…
Rank33.6
Comprehensive review of natural products targeting lapatinib resistance-related pathways in breast cancer as future strategies to overcome lapatinib resistance.
Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026 · PMID 42607556
BACKGROUND: Lapatinib (LAP) significantly improves outcomes in HER2-positive (HER2+) breast cancer, including trastuzumab-resistant p95HER2-expressing tumors. However, primary and acquired resistance remain unmet clinical challenges. Multiple studies have highlighted the promising role of natural products in breast cancer therapy. Given their ability to modulate multiple oncogenic signaling pathways, these compounds also represent potential therapeutic agents for overcoming LAP resistance. PURPOSE: In this review, …
Rank32.9
Early local immune activation following intra-operative radiotherapy in human breast tissue.
Oncoimmunology · 2026 · PMID 41943280
The local immune effects of cancer radiotherapy remain poorly characterized in humans due to limited access to irradiated tissue. Mechanistic insights largely derive from preclinical models employing tumor-intact, neoadjuvant-like settings. Here, we present real-world immunoprofiling data from breast cancer patients undergoing breast-conserving surgery with (n = 20) or without (n = 29) intraoperative radiotherapy (IORT). Postoperative wound fluid samples were analyzed by flow cytometry, multiplex cytokine profiling…
Rank32.0
Development and ICH M10-compliant validation of an LC-MS/MS method for quantification of atirmociclib in mouse plasma and its application to preclinical pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 · PMID 42669270
Atirmociclib is a selective cyclin-dependent kinase 4 (CDK4) inhibitor currently under clinical investigation for the treatment of advanced malignancies, particularly hormone receptor positive (HR+) or human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Here, we report the first validated liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method for the quantification of atirmociclib in mouse plasma, validated in compliance with international council for harmonisation-M10 (…
Rank31.7
An In Vitro and In Vivo Assessment of the Anti-Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts.
Cancer reports (Hoboken, N.J.) · 2026 · PMID 42676183
BACKGROUND: Breast cancer remains a topic of interest due to its high mortality rate among Cameroonian women. The barks of Erythrina excelsa are traditionally used for medicinal purposes in the management of various conditions including cancer. AIMS: This study evaluated the phytochemical composition, antioxidant properties, and anticancer effects of Erythrina excelsa bark extract in vitro and in vivo. METHODS AND RESULTS: Phytochemical profiling and antioxidant assays (DPPH, FRAP) were conducted to determine secon…
Rank31.4
Precise sequential combination of cisplatin and cyclophosphamide induces higher anti-tumor and immunomodulatory effects against experimental Ehrlich ascites.
Immunology letters · 2026 · PMID 42251904
BACKGROUND: Cisplatin (CIS) and cyclophosphamide (CTX) are commonly used in clinical oncology, often in combination to improve therapeutic outcomes. However, most preclinical studies have examined these agents individually, overlooking the potential synergistic and immunomodulatory effects of combined treatment. This study aimed to compare the antitumor and immune-modulating effects of single versus combined CTX and CIS chemotherapy, and to determine the treatment sequence that achieves maximum efficacy with minima…
Rank30.6
Design and biological evaluation of a histidine-bearing cyclometalated Pd(II) complex derived from 2-phenylpyridine.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026 · PMID 42446607
A rationally designed approach was employed to synthesize a new C^N-cyclometalated Pd(II) complex (C^N = 2-phenylpyridine) as a potential anticancer metallodrug. The incorporation of histidine in the coordination sphere of metal complex offers dual effect, balancing hydrophobic and hydrophilic properties while enhancing biocompatibility. The structure of histidine-bearing C^N-cyclometalated Pd(II) complex was characterized using elemental analysis, FT-IR, and NMR spectroscopy. In vitro cytotoxic activity was evalua…
Promising Experimental Therapies94 records
Rank106.6
The Effects of Guided Imagery on Women's Health: A Systematic Review of Experimental Studies.
International journal of environmental research and public health · 2026 · PMID 42652381
BACKGROUND: Guided imagery (GI) is a mind-body intervention that uses sensory visualizations to promote relaxation and healing. While being utilized in various clinical settings, its specific cumulative impact on women's health across different life stages remains to be comprehensively synthesized. This systematic review aims to evaluate the effectiveness of GI on psychological and physiological outcomes in women's health, including gynecologic/breast cancer, pregnancy, childbirth, and menopause. METHODS: A systema…
Rank105.2
Digital Health Interventions and Psychosocial Outcomes in Women With Breast Cancer: Systematic Review.
JMIR cancer · 2026 · PMID 42627958
BACKGROUND: Breast cancer and its treatment can negatively affect women's quality of life (QoL), including physical, psychological, and social well-being. Digital health interventions have been increasingly used to provide supportive care, but their effectiveness on QoL and related psychosocial outcomes remains unclear. OBJECTIVE: This review aimed to evaluate the effectiveness of digital health interventions on QoL in women with breast cancer and to assess their effects on anxiety, depression, and self-efficacy. M…
Rank100.0
Application and prospect of organoid technology in breast cancer.
Frontiers in immunology · 2024 · PMID 39253075
Breast cancer is the most common malignant tumor in women. Due to the high heterogeneity of breast cancer cells, traditional in vitro research models still have major limitations. Therefore, it is urgent to establish an experimental model that can accurately simulate the characteristics of human breast cancer. Breast cancer organoid technology emerged as the times required, that is, to construct tissue analogs with organ characteristics by using a patient's tumor tissue through 3D culture in vitro. Since the breast…
Rank98.9
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42492022
PURPOSE: Adjuvant radiotherapy for node-positive breast cancer (BC) using 50Gy/25fx has been Danish Breast Cancer Group (DBCG) standard. Hypofractionated radiotherapy based on 40Gy/15fx has been increasingly used; however, it is less frequently for locoregional therapy because of concern over more morbidity. DBCG Skagen trial 1 hypothesized that 40Gy/15fx did not cause more lymphedema than 50Gy/25fx 3 years after radiotherapy without compromising the pattern of failure. METHODS: Skagen trial 1 is a phase III, nonin…
Rank97.8
French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
BMJ open · 2026 · PMID 42665344
INTRODUCTION: Symptoms associated with vulvovaginal atrophy affect up to 73% of patients with breast cancer, whether menopausal or non-menopausal, because certain breast cancer treatments are responsible for oestrogen deprivation on the genital tract. These symptoms are currently underdiagnosed and undertreated but can significantly impair the quality of life and can be a cause of premature discontinuation of adjuvant hormone therapy. Treatment of vulvovaginal atrophy in patients managed for breast cancer should be…
Rank96.0
Effectiveness of Sentimag technology (Magseed and Magtrace localization) compared to traditional care for the management of early breast cancer: a systematic review protocol.
JBI evidence synthesis · 2026 · PMID 41536188
OBJECTIVE: This systematic review aims to evaluate the effectiveness, safety, and patient- and surgeon-related outcomes of the Sentimag platform (Magseed and Magtrace) as alternatives to traditional localization techniques in the surgical management of early breast cancer. INTRODUCTION: Magseed and Magtrace are magnetic localization technologies increasingly used to replace traditional wire-guided and radioisotope techniques for tumor and sentinel lymph node localization in breast-conserving surgery. While the tech…
Rank95.6
The Effect of Virtual Reality on Chemotherapy-Associated Stress (Cortisol Value), Anxiety, and Pain Symptoms of Mastectomy Patients: A Randomized Controlled Pilot Study.
Cancer nursing · 2026 · PMID 40179266
BACKGROUND: Pain, anxiety, and stress are the most common symptoms experienced by patients receiving chemotherapy after breast surgery. Virtual reality (VR) can be used as a method to manage these symptoms. OBJECTIVE: To determine the effect of VR on chemotherapy-associated stress (salivary cortisol value), anxiety, pain, and vital signs of mastectomy patients. METHODS: A total of 62 participants were enrolled in this randomized, 2-group design. Participants in the experimental group watched videos with VR glasses …
Rank95.5
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
Nature communications · 2026 · PMID 42649154
Pre-clinical evidence suggests that stereotactic ablative body radiotherapy (SABR) can enhance systemic anti-tumor responses when combined with immune checkpoint inhibition, although optimal fractionation remains uncertain. Here we conducted a phase II multi-center randomized trial (AZTEC trial; ClinicalTrials.gov identifier NCT03464942) to investigate the efficacy and safety of single-fraction (SF: 20 Gy; n = 27) or multi-fraction (MF: 24 Gy in three fractions; n = 27) SABR followed by anti-PD-L1 atezolizumab in 5…
Rank94.0
A laddered training model for breast surgery specialists: development and validation of a CBME-based precision education framework.
BMC medical education · 2026 · PMID 42321739
OBJECTIVE: This study aimed to develop a stepwise training model for breast surgery residents and evaluate its efficacy in improving operative skills, clinical decision-making, and patient management competencies within a Competency-Based Medical Education (CBME) framework. METHODS: The study was conducted in the Breast Surgery Department of the Second Affiliated Hospital, Zhejiang University School of Medicine. Twenty surgical residents in their second or third year of standardized training were enrolled and rando…
Rank92.6
Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation.
PloS one · 2026 · PMID 42594101
BACKGROUND: Chemotherapy-induced alopecia (CIA) remains one of the most distressing adverse effects for patients with localized breast cancer receiving anthracycline and taxane-based chemotherapy regimens. Although automated scalp cooling systems and standard non-automated cold-cap devices have demonstrated efficacy in reducing CIA, controlled trials with direct randomization comparing these two modalities of scalp cooling are lacking. This study aims to compare clinical efficacy, patient-reported outcomes, and med…
Rank92.0
Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader.
Journal of clinical pharmacology · 2026 · PMID 42572241
Population pharmacokinetic (PK) and exposure-response analyses were performed to characterize the PK and exposure-response relationships of vepdegestrant, a first-in-class, oral PROteolysis-TArgeting Chimera estrogen receptor degrader. Population PK and exposure-response analyses for safety utilized data from the first-in-human study (ARV-471-mBC-101, NCT04072952) and the registrational VERITAC-2 study (NCT05654623), which included patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative …
Rank92.0
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42048392
PURPOSE: Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle. PATIENTS AND METHODS: In part A (analytic validity phase), patients with stage II-III TNBC were randomized to FDG or FLT imaging. Baseli…
Rank92.0
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42189888
PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating the safety and efficacy of first-line treatment combinations with durvalumab (anti-PD-L1 antibody) for locally advanced, unresectable/metastatic TNBC (mTNBC; NCT03742102). In this study, we report results of 3 treatment arms. PATIENTS AND METHODS: Eligible female participants (≥18 years with untreate…
Rank92.0
Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.
Signal transduction and targeted therapy · 2026 · PMID 42572030
Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patients were women aged 18-75 years with HER2-negative locally advanced or metastatic breast cancer and germline BRCA mutations. Patients were assigned randomly (2:2:1) to receive TSL-1502 at 350 mg or 500 …
Rank92.0
Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.
Cell reports. Medicine · 2026 · PMID 42561949
In this phase 2 trial (NCT05582499), patients with stage II-III hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer were categorized into endocrine-based and targeted-based groups based on previously proposed similarity network fusion (SNF) subtyping by digital pathology classification and were then randomly assigned in a 1:1 ratio to receive precision or control treatment. The primary endpoint was pathological complete response (pCR). Among 251 randomized patients,…
Rank92.0
Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
Cell reports. Medicine · 2026 · PMID 42561946
Poor therapeutic response in subsets of breast cancer (BC) patients poses an ongoing challenge. Here, we present a biomarker-guided characterization of 40 patient-derived BC organoids, with the aim of modeling resistant disease with greater fidelity and developing an in vitro system grounded in clinical data for testing alternative treatment strategies. We utilize patient data from the I-SPY2 clinical trial (NCT01042379) to develop predictive models of response to a range of therapies, using only organoid-detectabl…
Rank92.0
Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42189890
PURPOSE: To independently validate that low endocrine transcriptional activity measured by the sensitivity to endocrine therapy (SETER/PR) index in hormone receptor-positive (HR+) breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. EXPERIMENTAL DESIGN: We conducted a blinded, prospective-retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FE…
Rank91.7
Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42154572
PURPOSE: The phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) activity contributing to this activation. Capivasertib is a potent pan-AKT inhibitor, approved in combination with fulvestrant for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer with one or more PIK3CA/AK…
Rank88.6
Evaluating the Effectiveness of a Mobile App for Breast Cancer Self-Management on Self-Efficacy: Nonrandomized Intervention Trial.
JMIR mHealth and uHealth · 2025 · PMID 40138696
BACKGROUND: Numerous mobile apps have been developed for patients with cancer. However, there is still no comprehensive app for patients with breast cancer that integrates evidence-based medical information, psychological support, and schedule management through a multidisciplinary medical approach. OBJECTIVE: We aimed to investigate whether a mobile app designed to assist in the self-management of patients with breast cancer is feasible and positively affects their self-efficacy and other psychological aspects. ME…
Rank83.4
Dalpiciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial.
Nature cancer · 2026 · PMID 42481711
Visceral crisis in advanced breast cancer (ABC) represents a major challenge. Here we conducted a phase 2 study to evaluate dalpiciclib plus endocrine therapy (ET) in women with HR+/HER2- ABC experiencing visceral crisis. The primary endpoint was the 6-month survival rate; secondary endpoints included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), 3-month treatment failure rate (TFR), duration of disease control (DDC), objective response rate (ORR), disease control rate (DC…
Rank81.5
A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41453455
PURPOSE: Although fractionated stereotactic radiation therapy (FSRT) remains understudied for the management of breast cancer brain metastases, this study aimed to investigate its therapeutic efficacy and safety in the context of contemporary systemic therapies. We enrolled patients with 1 to 10 brain lesions. METHODS AND MATERIALS: This was a prospective, single-arm, phase 2 trial involving 173 patients with breast cancer and 436 brain metastases, all treated with FSRT at a dose of 3 to 5 fractions of 8 Gy each. T…
Rank81.3
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies.
ESMO open · 2026 · PMID 42419085
BACKGROUND: To evaluate the activity and safety of trastuzumab-pkrb plus gedatolisib in patients with treatment-refractory human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) harboring phosphatidylinositol 3-kinase (PI3K) pathway alterations. PATIENTS AND METHODS: In this multicenter, single-arm phase II study, eligible patients had HER2-positive MBC with PI3K pathway aberrations identified by tumor or circulating cell-free DNA and had progressed after at least two prior HER2-dir…
Rank81.0
Phase 1-2 Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy.
International journal of radiation oncology, biology, physics · 2025 · PMID 39788388
PURPOSE: In patients with breast cancer, prone radiation therapy (RT) has been shown to reduce heart and lung dose. Though prone positioning is routinely used for whole breast RT, its use when treating the regional lymph nodes is not widespread. METHODS AND MATERIALS: In this phase 1/2 trial for stage IB-IIA breast cancer treated with lumpectomy or mastectomy, patients received 40.5 Gy in 15 fractions to the breast or chest wall and regional lymph nodes with an integrated tumor bed boost for lumpectomy patients. Pr…
Rank80.7
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
Clinical breast cancer · 2026 · PMID 42431148
INTRODUCTION: Recent advances in HER2-directed therapies have improved outcomes for patients with HER2+ advanced/metastatic breast cancer (a/mBC), but disease progression ultimately occurs in most cases. Dual targeting of HER2 with tyrosine kinase inhibitors and antibody-drug conjugates has the potential for non-cross-resistant treatments that improve disease control. METHODS: HER2CLIMB-04, a single-arm, open-label, phase 2 study, evaluated tucatinib plus trastuzumab deruxtecan (T-DXd) in patients with HER2+ a/mBC …
Rank80.4
Preoperative Single Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer Patients With GammaPod Technology: Pathologic Findings and Ki-67 Evaluation.
International journal of radiation oncology, biology, physics · 2025 · PMID 39993536
PURPOSE: The purpose of this phase 2 clinical study is to investigate the safety and feasibility of a single fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer in the preoperative setting and to evaluate tumor response to a single large radiation dose through pathologic examination and immunohistochemistry analysis of the surgical specimen. METHODS AND MATERIALS: This single arm, phase 2 clinical trial includes patients in postmenopausal status, over the age of 50 years, with ear…
Prospective Cohort Studies88 records
Rank110.0
Sensitive Period Analysis of Adulthood BMI and Cancer Risk: An Individual Participant Data Meta-Analysis of Over 720,000 Participants in the ABACus 2 Consortium.
International journal of cancer · 2026 · PMID 41952250
At least 13 cancers are linked to obesity. We analyse time-to-event data using Sensitive Period Analysis to explore whether associations between body mass index (BMI) and cancer incidence vary throughout adulthood to inform cancer prevention strategies, policy and weight management trials of optimal intervention ages. Using the European Prospective Investigation into Cancer and Nutrition cohort, Atherosclerosis Risk in Communities study, Women's Health Initiative, Prostate, Lung, Colorectal, Ovarian Cancer Screenin…
Rank109.9
Post-Diagnostic Diet and Breast Cancer Outcomes: A Comprehensive Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
Nutrients · 2026 · PMID 42654166
Background/Objectives: Diet is increasingly recognized as a modifiable factor in cancer survivorship; however, the impact of post-diagnostic dietary habits on breast cancer (BC) outcomes remains uncertain. This systematic review aimed to evaluate the association between diet after BC diagnosis and clinical outcomes and to provide an updated synthesis of the evidence, with particular emphasis on dietary assessment methods, methodological heterogeneity, and evidence gaps. Methods: We systematically reviewed randomize…
Rank108.5
Second-To-Fourth Digit Ratio (2D:4D) in Breast Cancer: A Systematic Review.
American journal of human biology : the official journal of the Human Biology Council · 2026 · PMID 42568130
INTRODUCTION: The second-to-fourth digit ratio (2D:4D) is considered an indirect marker of prenatal sex hormone exposure and has been investigated as a potential indicator of susceptibility to hormone-related diseases, including breast cancer. The purpose of this systematic review is to evaluate the relationship between the 2D:4D finger ratio and breast cancer risk. METHODS: This systematic review was conducted in accordance with the PRISMA 2020 statement. PubMed, Scopus, and Web of Science were searched without pu…
Rank100.4
Association of mobile application information on multidisciplinary therapy and treatment compliance in early-stage breast cancer: A prospective multicenter randomized phase III study.
Breast (Edinburgh, Scotland) · 2026 · PMID 42150214
BACKGROUND: Multidisciplinary therapy (MDT) can improve early breast cancer outcome, while its treatment completion rate is critical. This study aimed to evaluate the association of a mobile health application (RJBC-APP) information on MDT and its treatment adherence, compared with standard clinical management. METHODS: The RJBC-APP study is a prospective, multicenter, randomized, phase 3 clinical trial that enrolled patients with early-stage breast cancer after MDT for adjuvant treatment. Eligible patients were ra…
Rank100.3
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.
BJS open · 2026 · PMID 42551036
BACKGROUND: Axillary lymph node dissection (ALND) in breast cancer causes substantial arm morbidity and long-term functional impairment. Less extensive axillary surgery, such as targeted axillary dissection (TAD), significantly reduces this risk. Although omission of ALND is standard in clinically node-negative disease with limited sentinel node involvement, this is not the case for patients with clinically node-positive disease undergoing upfront surgery. The aim of the SENOMAC-ULTRA trial is to evaluate whether T…
Rank100.0
Current evidence on the prospective predictors and trajectories of posttraumatic growth and depreciation in adult women with breast cancer: a systematic review of longitudinal studies.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42576029
PURPOSE: Breast cancer remains a global health concern, with post-traumatic psychological changes, both positive and negative, during treatment and survivorship. This systematic review aimed to examine the prospective predictors of Posttraumatic Growth (PTG) and Posttraumatic Depreciation (PTD), as well as their temporal dynamics in women diagnosed with breast cancer. METHODS: PubMed, Scopus, CINAHL, and PsycINFO were systematically searched on 31st January 2025, using a combination of terms and Boolean operators, …
Rank97.6
Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.
Journal of the Egyptian National Cancer Institute · 2026 · PMID 42684555
BACKGROUND: Sentinel lymph node biopsy (SLNB) is standard for axillary staging in early breast cancer. While the combination of radioisotope and blue dye (e.g., patent blue V, PBV) remains the standard, it has limitations including logistics, variable identification rate (IR), and allergic potential. Indocyanine green (ICG) fluorescence is a promising alternative, but high-quality comparative evidence is needed. METHODS: This was a single-center, prospective, randomized controlled trial. Forty patients with early-s…
Rank94.6
Differential effects of sevoflurane versus propofol on calmodulin expression in breast cancer patients.
Pakistan journal of pharmaceutical sciences · 2026 · PMID 42262213
BACKGROUND: Evidence from experimental and clinical studies suggests that anesthetic drugs may modulate tumor biology by influencing immune regulation, inflammation and intracellular calcium signaling. However, the extent to which sevoflurane or propofol alters calcium-related molecular expression in human breast cancer tissue remains unclear. OBJECTIVES: This study aimed to compare the effects of sevoflurane- versus propofol-based anesthesia on calcium signaling pathway-related gene and protein expression in breas…
Rank94.5
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
The Lancet. Oncology · 2026 · PMID 42636839
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are a robust prognostic marker in patients with triple-negative breast cancer. Artificial intelligence (AI)-derived computational tools assessing TILs could improve efficiency, but require independent validation against clinical outcomes. We aimed to compare the prognostic performance of AI-derived TIL scores with pathologist-scored TILs in a large, prospectively collected dataset pooled from randomised controlled trials. METHODS: CATALINA was an independent, exter…
Rank92.6
Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation.
PloS one · 2026 · PMID 42594101
BACKGROUND: Chemotherapy-induced alopecia (CIA) remains one of the most distressing adverse effects for patients with localized breast cancer receiving anthracycline and taxane-based chemotherapy regimens. Although automated scalp cooling systems and standard non-automated cold-cap devices have demonstrated efficacy in reducing CIA, controlled trials with direct randomization comparing these two modalities of scalp cooling are lacking. This study aims to compare clinical efficacy, patient-reported outcomes, and med…
Rank90.9
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer.
Breast (Edinburgh, Scotland) · 2026 · PMID 42330688
BACKGROUND: IMpassion130 trial results led to approval of first-line atezolizumab plus nab-paclitaxel for PD-L1-positive advanced triple-negative breast cancer (aTNBC). The global single-arm EL1SSAR study (NCT04148911) enrolled a broader patient population to elucidate outcomes in routine practice. METHODS: Patients with measurable PD-L1-positive aTNBC and no prior systemic therapy for advanced disease received atezolizumab (840 mg, days 1&15) plus nab-paclitaxel (100 mg/m2, days 1,8,15) every 28 days until disease…
Rank88.6
Auricular Acupressure for Perioperative Anxiety and Pain in Therapeutic Breast Surgery: Protocol for a Randomized Clinical Trial.
JMIR research protocols · 2026 · PMID 42627947
BACKGROUND: Preoperative anxiety is common among women undergoing breast cancer surgery and is associated with impaired subjective well-being as well as adverse perioperative outcomes, including increased postoperative pain, nausea and vomiting, and higher analgesic requirements. While preliminary evidence suggests potential benefits of nonpharmacological interventions, including acupuncture, robust clinical evaluation of safe and feasible approaches in perioperative oncology is still needed. The National Acupunctu…
Rank84.0
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
JAMA oncology · 2026 · PMID 42348190
IMPORTANCE: The neoadjuvant combination of paclitaxel, trastuzumab, and pertuzumab (THP) represents a promising abbreviated regimen for early-stage ERBB2-positive breast cancer, but long-term outcomes and the role of ultrasensitive circulating tumor DNA (ctDNA) monitoring remain incompletely defined. OBJECTIVE: To assess 5-year outcomes and characterize ctDNA dynamics with an ultrasensitive assay in patients with ERBB2-positive breast cancer receiving neoadjuvant THP. DESIGN, SETTING, AND PARTICIPANTS: This study w…
Rank81.5
A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41453455
PURPOSE: Although fractionated stereotactic radiation therapy (FSRT) remains understudied for the management of breast cancer brain metastases, this study aimed to investigate its therapeutic efficacy and safety in the context of contemporary systemic therapies. We enrolled patients with 1 to 10 brain lesions. METHODS AND MATERIALS: This was a prospective, single-arm, phase 2 trial involving 173 patients with breast cancer and 436 brain metastases, all treated with FSRT at a dose of 3 to 5 fractions of 8 Gy each. T…
Rank80.2
Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy.
Breast (Edinburgh, Scotland) · 2026 · PMID 42214154
BACKGROUND: Preoperative immuno-chemotherapy improves outcomes in triple-negative breast cancer, but associated imaging response patterns remain poorly characterized. This study aimed to describe a novel MRI phenomenon, tumor flare-like response (TFLR), and evaluate its association with pathological complete response (pCR). METHODS: Ad hoc imaging analysis of a prospective phase II trial (NCT04213898; n = 39). Breast MRI was performed at baseline and after every two cycles. TFLR was defined a priori as new enhancin…
Rank79.1
Long-Term Shoulder Dysfunction After Breast and Axillary Surgery: Impact of Surgical Extent and Predictors of Function.
ANZ journal of surgery · 2026 · PMID 42157559
PURPOSE: To evaluate long-term shoulder outcomes after sentinel lymph-node biopsy (SLNB) versus axillary lymph-node dissection (ALND) and identify predictors of chronic shoulder dysfunction. MATERIAL AND METHODS: This prospective multicenter study enrolled 1111 women (≥ 18 years) undergoing breast cancer surgery with SLNB (n = 931) or ALND (n = 180) across five tertiary hospitals between October 2022 and June 2024. Functional outcomes were assessed using QuickDASH, range-of-motion (ROM), daily-activity limitations,…
Rank79.0
Breath analysis for non-invasive detection of breast cancer: A prospective observational cohort study.
Tumori · 2026 · PMID 42037599
PURPOSE AND DESIGN: BreathBC is a multicenter prospective observational cohort study aimed at comparing metabolic profiles from exhaled breath of patients with breast cancer (BC) and malignancy-free controls. The study accounts for the novelty and complexity of breath analysis, with a particular emphasis on the standardization of each step in the process. PARTICIPANTS: Women with primary BC without distant metastasis, women carriers of germline BRCA1/2 pathogenic variants and controls were consecutively recruited i…
Rank78.0
Carbon-Ion Radiation Therapy as Nonsurgical Treatment for Early-Stage Breast Cancer: 5-Year Results From the Phase 2 Part of the First Prospective Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 42108880
PURPOSE: To evaluate the long-term efficacy, safety, and cosmetic outcomes of carbon-ion radiation therapy (C-ion RT) as a nonsurgical treatment option for patients with early-stage breast cancer. METHODS AND MATERIALS: This single-center, prospective phase 1/2 trial enrolled women aged ≥60 years with stage I (cT1N0M0), estrogen receptor-positive, human epidermal growth factor receptor type 2-negative invasive ductal carcinoma, ≤2 cm in diameter. Patients received C-ion RT at a total dose of 60 Gy (relative biologi…
Rank77.6
CRYOTHERAPY FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY IN BREAST CANCER: A PROSPECTIVE MULTICENTER STUDY.
Georgian medical news · 2026 · PMID 42603324
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of taxane-based chemotherapy in breast cancer. Cryotherapy using cooling gloves and socks has been investigated as a preventive strategy, although evidence remains inconsistent. This study evaluated the effect of preventive cryotherapy on neuropathy-related pain and symptom burden in patients receiving taxane-containing chemotherapy. METHODS: This prospective multicenter controlled study included patients with stage I-I…
Rank77.0
Indocyanine green use, detection and safety in patients with breast cancer undergoing sentinel lymph node biopsy: A French prospective observational study.
Surgical oncology · 2026 · PMID 42296697
BACKGROUND: Sentinel lymph node (SLN) biopsy is the standard procedure for staging patients with early-stage breast cancer. Indocyanine green (ICG), a near-infrared fluorescent dye, has emerged as an alternative to other colorimetric and radioactive tracers for SLN mapping that has high sensitivity and is rarely allergenic. METHODS: The Observational Assess SLN Infracyanine® (ICG) Surgery (OASIS) study was a prospective, multicenter, observational, single-arm study that enrolled 101 female patients with breast canc…
Rank77.0
Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 40912507
PURPOSE: This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a postoperative treatment in patients with early-stage, hormone-positive breast cancer. It aims to assess acute and late treatment-related toxicity, cosmesis, patient-reported quality of life (QoL), and oncologic outcomes. METHODS AND MATERIALS: This single-institution, single-arm, phase 2 prospective trial included postmenopausal women ≥50 years with early-stage, hormone-positive breast …
Rank76.6
Optimizing breast conservative surgery for ductal carcinoma in situ: Comparative outcomes of intraoperative ultrasound and wire localization in achieving negative margins.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42247964
BACKGROUND: Intraoperative ultrasound-guided surgery (IOUS) is an effective technique for invasive breast cancer, offering advantages over wire localization (WL), such as smaller resection volumes, lower rates of involved margins, and better patient satisfaction. However, evidence for ductal carcinoma in situ (DCIS) is limited. This study aimed to compare specimen margins and excision volume in DCIS treated with IOUS versus WL. MATERIAL AND METHODS: From February 2018 to December 2023, women diagnosed with DCIS and…
Rank76.2
Clinical experience and satisfaction in patients with advanced breast cancer participating in the abemaciclib patient support program in Spain: a prospective observational study.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41817657
PURPOSE: To evaluate the impact of a patient support program (PSP) on the management of abemaciclib-related diarrhea in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) and its influence on adherence and patient-reported outcomes in routine clinical practice. METHODS: This is a multicenter, prospective, observational Spanish study in patients with locally advanced or MBC receiving abemaciclib and enrolled in the PSP, assessed over …
Rank75.6
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Gynecologic oncology · 2026 · PMID 42447658
BACKGROUND: Abemaciclib inhibits cyclin dependent kinases (CDK) 4 and 6 and, in synergy with anti-estrogens, is an FDA approved treatment of ER+ breast cancer. We hypothesized that letrozole and abemaciclib will inhibit cellular proliferation in patients with endometrial cancer. METHODS: This is a single-arm prospective multicenter surgical window of opportunity clinical trial for patients with endometrial cancer planned to undergo definitive management with hysterectomy. Patients received 14 days of abemaciclib 15…
Rank74.5
Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42406276
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy are the standard first- and second-line treatments for hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). In clinical practice, however, CDK4/6 inhibitors are also used in patients previously treated with chemotherapy, but their efficacy and safety in this setting remain unclear. PATIENTS AND METHODS: We conducted a multi-institutional prospective cohort study to obt…
Quality Of Life111 records
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.0
The associations between household food insecurity and cancer: A comprehensive systematic review and meta-analysis of observational studies among adults.
Social science & medicine (1982) · 2026 · PMID 42685390
BACKGROUND: Household food insecurity (HFI) is a critical social determinant of health that can adversely influence cancer prevention, treatment, and survivorship, while a cancer diagnosis with its financial and functional consequences may also increase the risk of HFI. This study aimed to examine the associations between HFI and cancer-related outcomes. METHODS: A systematic search was done in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until July 29, 2025. Eligible studies were observational in a…
Rank105.8
Emotional freedom techniques for cancer-related sleep disturbance and associated symptoms: A systematic review and meta-analysis.
Complementary therapies in medicine · 2026 · PMID 42595020
BACKGROUND: Cancer patients frequently experience a debilitating and interconnected symptom cluster comprising pain, fatigue, and sleep disturbance (P-F-S), which negatively impacts their quality of life and treatment outcomes. Emotional Freedom Techniques (EFT), a mind-body intervention combining cognitive exposure with acupoint stimulation, has shown potential for addressing psychological distress, yet its effectiveness on this specific physiological symptom cluster remains underexplored. OBJECTIVES: This systema…
Rank105.7
Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.
Anales del sistema sanitario de Navarra · 2026 · PMID 42657993
Background Hormone receptor-positive breast cancer is treated with endocrine therapies to reduce recurrence and mortality. These therapies have side effects that negatively affect quality of life (QoL). We aim to synthesize the available evidence on the impact of non-pharmacological interventions on QoL and its specific domains (physical, psychological, social, and spiritual) in female breast cancer survivors undergoing endocrine therapies. Methods A systematic review following the Cochrane and PRISMA guidelines wa…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank105.2
Digital Health Interventions and Psychosocial Outcomes in Women With Breast Cancer: Systematic Review.
JMIR cancer · 2026 · PMID 42627958
BACKGROUND: Breast cancer and its treatment can negatively affect women's quality of life (QoL), including physical, psychological, and social well-being. Digital health interventions have been increasingly used to provide supportive care, but their effectiveness on QoL and related psychosocial outcomes remains unclear. OBJECTIVE: This review aimed to evaluate the effectiveness of digital health interventions on QoL in women with breast cancer and to assess their effects on anxiety, depression, and self-efficacy. M…
Rank102.6
Meta-analysis of the effect of sexual health nursing interventions on improving post-treatment sexual dysfunction and partner relationship satisfaction in breast cancer patients.
Sexual medicine · 2026 · PMID 42540624
INTRODUCTION: Breast cancer survivors frequently experience sexual dysfunction and impaired partner relationships after treatment, but the effectiveness of nursing interventions in improving these post-treatment outcomes remains uncertain. To evaluate the efficacy of sexual health, nursing interventions on sexual dysfunction and quality of life in breast cancer survivors through a systematic review and meta-analysis of randomized controlled trials. METHODS: We searched PubMed, Embase, and Web of Science for randomi…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.3
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.
BJS open · 2026 · PMID 42551036
BACKGROUND: Axillary lymph node dissection (ALND) in breast cancer causes substantial arm morbidity and long-term functional impairment. Less extensive axillary surgery, such as targeted axillary dissection (TAD), significantly reduces this risk. Although omission of ALND is standard in clinically node-negative disease with limited sentinel node involvement, this is not the case for patients with clinically node-positive disease undergoing upfront surgery. The aim of the SENOMAC-ULTRA trial is to evaluate whether T…
Rank100.0
Measures of Thriving in Breast Cancer: A COSMIN Systematic Review of Psychometric Properties.
Oncology nursing forum · 2026 · PMID 42690383
PROBLEM IDENTIFICATION: Thriving, a construct reflecting personal growth, resilience, and emotional vitality after adversity, is gaining attention in oncology and health-related quality-of-life research. However, consensus is lacking on which patient-reported outcome measures (PROMs) best assess thriving in individuals with breast cancer. LITERATURE SEARCH: A systematic search across nine databases identified studies reporting the development or psychometric evaluation of PROMs for thriving in adults. DATA EVALUATI…
Rank100.0
Impact of Exercise on QOL, Cardiorespiratory Function, and Inflammatory Markers in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Oncology nursing forum · 2026 · PMID 42690380
PROBLEM IDENTIFICATION: Breast cancer is the most common cancer type in women globally. Although survival rates have improved, treatments cause lasting issues, including impaired cardiorespiratory fitness, chronic inflammation, and reduced quality of life (QOL). Exercise is recommended to alleviate these burdens, but evidence remains inconsistent regarding its effects on cardiorespiratory function, inflammatory markers, and QOL, with limited integrated evaluation. LITERATURE SEARCH: A systematic search was conducte…
Rank100.0
Effects of exercise interventions on sleep quality in breast cancer survivors: a systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42676424
BACKGROUND: The probability of postoperative sleep disturbances in breast cancer survivors exceeds 60%. Poor sleep quality substantially undermines quality of life, exacerbates fatigue, and impairs postoperative recovery. OBJECTIVE: To systematically review the effects of exercise interventions on sleep quality in breast cancer survivors and explore whether effect estimates vary according to exercise intervention characteristics. METHODS: We searched PubMed, Web of Science, Embase, and the Cochrane Library from inc…
Rank100.0
Sexual intimacy after breast cancer: A systematic review of qualitative studies on women's and partners' experiences in dating and romantic relationships.
Body image · 2026 · PMID 42603448
Body changes related to breast cancer treatment are associated with body image concerns and sexual and intimacy difficulties that adversely affect quality of life, yet remain frequently unaddressed by healthcare professionals. Although existing reviews have examined these challenges among women with breast cancer, none have synthesised qualitative evidence incorporating partners' perspectives or spanning different intimate partnerships, including dating and emerging relationships. This systematic review aimed to sy…
Rank97.8
French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
BMJ open · 2026 · PMID 42665344
INTRODUCTION: Symptoms associated with vulvovaginal atrophy affect up to 73% of patients with breast cancer, whether menopausal or non-menopausal, because certain breast cancer treatments are responsible for oestrogen deprivation on the genital tract. These symptoms are currently underdiagnosed and undertreated but can significantly impair the quality of life and can be a cause of premature discontinuation of adjuvant hormone therapy. Treatment of vulvovaginal atrophy in patients managed for breast cancer should be…
Rank97.2
Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment.
Clinical breast cancer · 2026 · PMID 42431149
BACKGROUND: Changes in patient-reported outcomes may be statistically significant, but not necessarily clinically significant. This study determined the minimal clinically important differences (MCIDs) in the Skin Symptom Assessment (SSA) questionnaire for the Mepitel film (MF) versus standard of care (SOC) randomized controlled trial for the prevention of radiation dermatitis (RD) in breast cancer patients. MCIDs are the smallest changes in patient-reported outcome measures (PROMs) that hold meaningful significanc…
Rank97.0
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
The oncologist · 2026 · PMID 42496653
BACKGROUND: We report ophthalmological assessments, patient-reported visual symptoms/functioning, and characterization of visual effect AEs from the SERENA-6 study. MATERIALS AND METHODS: This double-blind, placebo-controlled phase III study included 315 patients with ER-positive advanced breast cancer receiving first-line aromatase inhibitor (AI)+CDK4/6 inhibitor (CDK4/6i). Patients with emerging ESR1 mutations in ctDNA and no radiological progression were randomized 1:1 to switch to camizestrant+CDK4/6i or contin…
Rank96.7
Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A Randomized Clinical Trial.
JAMA network open · 2026 · PMID 42658497
IMPORTANCE: Women receiving chemotherapy for breast cancer experience insomnia and fatigue, which impair quality of life. To date, no randomized clinical trial (RCT) has evaluated the use of cognitive behavior therapy for insomnia (CBT-I) and bright light therapy (BLT) both alone and in combination, and few have evaluated the use of either during chemotherapy. OBJECTIVE: To determine the main effects of CBT-I and BLT on insomnia and fatigue symptoms in women undergoing chemotherapy for breast cancer. DESIGN, SETTIN…
Rank96.0
Impact of breast reconstruction on sexual function and body image in breast cancer survivors: A systematic review.
JPRAS open · 2026 · PMID 42376013
BACKGROUND: Breast cancer remains the most prevalent malignancy among women globally. As survival rates improve, the clinical focus has shifted toward the quality of life (QoL) and psychosexual survivorship. This systematic review evaluates the impact of breast reconstruction (BR) on sexual function and body image in breast cancer survivors compared to mastectomy alone. METHODS: A systematic literature search was conducted in PubMed following PRISMA guidelines (January 2016-January 2026). Methodological quality was…
Rank96.0
Social prescribing and supported self-management: A scoping review of the potential for implementation in non-surgical oncology services.
Journal of medical imaging and radiation sciences · 2026 · PMID 42407269
BACKGROUND: Social prescribing and supported self-management are two components of the National Health Service (NHS) personalised care model and have proven effectiveness in primary care settings. Social prescribing is a range of non-clinical services that address the psychological, psychosocial, and environmental issues affecting a person's well-being. Patients undertake supported self-management tasks to increase their knowledge, skills, and confidence in managing their health and medical care. However, these pra…
Rank96.0
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42647767
PURPOSE: To provide recommendations on use of medical therapies for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer. METHODS: An Expert Panel including patient representation completed a systematic review of the evidence and formulated recommendations for practice. Eligible studies included patients with stage I-III hormone receptor-positive, HER2-negative breast cancer and evaluated neoadjuvant or adjuvant chemotherapy, endocrine therapy, immunotherapy, or targeted therapy. Outcome…
Rank96.0
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41541190
OBJECTIVE: The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological distress that often overlaps with anxiety, depression, and fear of recurrence. Many existing interventions neglect the unique psychosocial contexts of BCSs, and unclear definitions of distress hinder consistent assessment and management. This systematic review evaluated recent interventions targeting psychological distress in BCSs and offers evidence-based insigh…
Rank96.0
Effects of transcutaneous electrical acupoint stimulation versus acupressure on the trajectories of multidimensional adverse reactions to chemotherapy in breast cancer patients: a secondary analysis of a randomized controlled trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42680887
BACKGROUND: Chemotherapy for breast cancer often induces multidimensional adverse reactions such as nausea and vomiting, anxiety, depression, and sleep disturbances. These symptoms are interrelated and may evolve dynamically, impacting patients' treatment outcomes and quality of life. As non-pharmacological interventions, transcutaneous electrical acupoint stimulation (TEAS) and self-acupressure (SA) have shown potential in alleviating symptoms. However, their long-term effects on the joint developmental trajectori…
Rank95.8
Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.
Cancer biotherapy & radiopharmaceuticals · 2026 · PMID 41645929
OBJECTIVE: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. METHODS: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n…
Randomized Controlled Trials120 records
Rank109.9
Post-Diagnostic Diet and Breast Cancer Outcomes: A Comprehensive Systematic Review of Prospective Cohort Studies and Randomized Clinical Trials.
Nutrients · 2026 · PMID 42654166
Background/Objectives: Diet is increasingly recognized as a modifiable factor in cancer survivorship; however, the impact of post-diagnostic dietary habits on breast cancer (BC) outcomes remains uncertain. This systematic review aimed to evaluate the association between diet after BC diagnosis and clinical outcomes and to provide an updated synthesis of the evidence, with particular emphasis on dietary assessment methods, methodological heterogeneity, and evidence gaps. Methods: We systematically reviewed randomize…
Rank109.7
Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.
Journal of neuro-oncology · 2026 · PMID 42550373
PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcomes, guidelines, and ongoing trials in TNBC-associated BM. METHODS: The review followed PRISMA guidance and was registered in the Open Science Framework (OSF.IO/6TDRF). MEDLINE, Scopus, Web of Science, DOAJ, and ClinicalTrials.gov we…
Rank108.5
The impact of menopausal status on the efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: a systematic review and meta-analysis of phase III clinical trials.
Breast cancer research and treatment · 2026 · PMID 42593586
PURPOSE: Adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) improve outcomes in hormone receptor-positive (HR+), HER2-negative early breast cancer, though trial results have been heterogeneous. Menopausal status and endocrine therapy backbone may contribute to variability in treatment effect. We performed a meta-analysis evaluating whether menopausal status influences the efficacy of adjuvant CDK 4/6 inhibition. METHODS: A systematic review of phase III randomized trials evaluating adjuvant CDK4/6i in HR+/HE…
Rank107.9
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Cancer control : journal of the Moffitt Cancer Center · 2026 · PMID 42619658
IntroductionAntibody-drug conjugates (ADCs) are now widely used in breast cancer across multiple disease subtypes. With increasing clinical use, treatment-related toxicities have become an important factor in therapeutic decision-making. However, comparative safety data among ADCs are limited because direct head-to-head trials are lacking.MethodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials evaluating ADCs in breast cancer, with the literature search updated thr…
Rank107.8
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Expert review of anticancer therapy · 2026 · PMID 42030172
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA). METHODS: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC.…
Rank107.1
Efficacy, safety, and PD-L1-defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42656671
BACKGROUND: Neoadjuvant immune checkpoint inhibitors combined with chemotherapy improve pathological complete response in early-stage triple-negative breast cancer, but the consistency of benefit, role of PD-L1 expression, and immune-related toxicity remain clinically relevant. METHODS: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to June 30, 2026, for randomized trials comparing neoadjuvant immune checkpoint inhibitors plus chemotherapy with chemotherapy alone…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.7
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors.
Journal of cancer survivorship : research and practice · 2025 · PMID 37906420
PURPOSE: Breast cancer survivors are more likely to report psychological distress and unmet need for support compared to healthy controls. Psychological mobile health interventions might be used in follow-up care of breast cancer patients to improve their mental health. METHODS: We searched MEDLINE, PsychINFO, Cochrane and PROSPERO for articles on controlled trials examining the effectiveness of psychological mobile health interventions compared to routine care regarding mental health outcomes of adult breast cance…
Rank106.6
The Effects of Guided Imagery on Women's Health: A Systematic Review of Experimental Studies.
International journal of environmental research and public health · 2026 · PMID 42652381
BACKGROUND: Guided imagery (GI) is a mind-body intervention that uses sensory visualizations to promote relaxation and healing. While being utilized in various clinical settings, its specific cumulative impact on women's health across different life stages remains to be comprehensively synthesized. This systematic review aims to evaluate the effectiveness of GI on psychological and physiological outcomes in women's health, including gynecologic/breast cancer, pregnancy, childbirth, and menopause. METHODS: A systema…
Rank106.6
Comparative Effects of Various Delivery Methods of Cognitive Behavioral Therapy for Insomnia Among Patients With Cancers: Systematic Review and Network Meta-Analysis.
Psycho-oncology · 2026 · PMID 42670890
BACKGROUND: Insomnia affects 30%-60% of cancer survivors, with around 20% meeting criteria for insomnia disorder. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment, but access is limited by cost and therapist availability, prompting exploration of alternative delivery modes, including digital interventions. PURPOSE: To systematically review and conduct a network meta-analysis (NMA) of the efficacy of different CBTi delivery methods for managing insomnia in cancer survivors. METHODS: The P…
Rank106.4
Erector spinae plane block (ESPB) versus paravertebral plane block (PVB) in managing post-operative pain in breast cancer patients: a systematic review and meta-analysis.
World journal of surgical oncology · 2026 · PMID 42632896
BACKGROUND: Breast cancer surgeries remain the cornerstone of treatment for early-stage disease. Nonetheless, a substantial proportion of patients experience moderate-to-severe acute or chronic postoperative pain, adversely affecting quality of life and functional recovery. Regional anesthetic techniques have emerged as effective strategies for perioperative pain control. This study compares the erector spinae plane block (ESPB) and the thoracic paravertebral block (PVB) in breast cancer surgeries. METHODS: Four da…
Rank106.4
The Effect of E-Health Interventions on Fear of Recurrence in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Seminars in oncology nursing · 2026 · PMID 41765743
INTRODUCTION: Fear of cancer recurrence (FCR) is among the most common and debilitating psychological issues affecting breast cancer survivors. With technological advances, e-health interventions have emerged as cost-effective tools to manage psychosocial challenges such as FCR. OBJECTIVES: This study aimed to systematically review and synthesize evidence from randomized controlled trials assessing the effectiveness of e-health interventions in reducing FCR among breast cancer survivors. METHODS: This systematic re…
Rank106.0
Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials.
Breast cancer research : BCR · 2025 · PMID 40598299
BACKGROUND: Given the rising incidence of breast cancer, especially in premenopausal women, there is an urgent need to identify additional risk-reducing medications to accelerate prevention, as only a few are currently approved. We, therefore, performed network meta-analysis (NMA) to identify and compare the efficacy of medications for primary breast cancer prevention. METHODS: We performed a literature search completed on November 16, 2023, in Embase, Ovid-Medline, Scopus, and Cochrane Library for randomized contr…
Rank106.0
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · 2026 · PMID 42289089
OBJECTIVE: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM). STUDY SELECTION: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidenc…
Rank105.8
Emotional freedom techniques for cancer-related sleep disturbance and associated symptoms: A systematic review and meta-analysis.
Complementary therapies in medicine · 2026 · PMID 42595020
BACKGROUND: Cancer patients frequently experience a debilitating and interconnected symptom cluster comprising pain, fatigue, and sleep disturbance (P-F-S), which negatively impacts their quality of life and treatment outcomes. Emotional Freedom Techniques (EFT), a mind-body intervention combining cognitive exposure with acupoint stimulation, has shown potential for addressing psychological distress, yet its effectiveness on this specific physiological symptom cluster remains underexplored. OBJECTIVES: This systema…
Rank105.7
Non-pharmacological interventions and quality of life in female survivors of hormone receptor-positive breast cancer receiving adjuvant endocrine therapy: A systematic review.
Anales del sistema sanitario de Navarra · 2026 · PMID 42657993
Background Hormone receptor-positive breast cancer is treated with endocrine therapies to reduce recurrence and mortality. These therapies have side effects that negatively affect quality of life (QoL). We aim to synthesize the available evidence on the impact of non-pharmacological interventions on QoL and its specific domains (physical, psychological, social, and spiritual) in female breast cancer survivors undergoing endocrine therapies. Methods A systematic review following the Cochrane and PRISMA guidelines wa…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank105.2
Digital Health Interventions and Psychosocial Outcomes in Women With Breast Cancer: Systematic Review.
JMIR cancer · 2026 · PMID 42627958
BACKGROUND: Breast cancer and its treatment can negatively affect women's quality of life (QoL), including physical, psychological, and social well-being. Digital health interventions have been increasingly used to provide supportive care, but their effectiveness on QoL and related psychosocial outcomes remains unclear. OBJECTIVE: This review aimed to evaluate the effectiveness of digital health interventions on QoL in women with breast cancer and to assess their effects on anxiety, depression, and self-efficacy. M…
Rank105.1
Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42690445
PURPOSE: Cancer therapy-related cardiac dysfunction (CTRCD) is a significant concern for breast cancer patients undergoing anthracycline-based chemotherapy. Although exercise has been proposed as a cardioprotective strategy, existing reviews have largely examined heterogeneous cancer populations receiving varied treatments, leaving a gap in the evidence base focused exclusively on anthracycline-induced CTRCD. This systematic review and meta-analysis aimed to address that gap by evaluating the effects of long-term e…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank104.3
Network meta-analysis of bisphosphonates in the treatment of bone metastases from breast cancer.
International journal of clinical pharmacology and therapeutics · 2026 · PMID 42290268
OBJECTIVE: Through a network meta-analysis, this study aimed to systematically evaluate the efficacy and safety of bisphosphonates in reducing skeletal-related events in patients with bone metastases from breast cancer, providing clinical guidance for treatment selection. MATERIALS AND METHODS: Randomized controlled trials (RCTs) on bisphosphonate therapy for bone metastases in breast cancer were retrieved from PubMed, Cochrane, and Embase databases from inception to January 2025. Statistical analyses were performe…
Rank103.2
Resistance Exercise and Skeletal Muscle-Related Outcomes in Patients with Cancer: A Systematic Review.
Medicine and science in sports and exercise · 2024 · PMID 38650124
BACKGROUND: Skeletal muscle loss is prevalent throughout the cancer continuum and correlated with morbidity and mortality. Resistance exercise has been trialed to mitigate skeletal muscle loss. This systematic review summarizes and qualitatively synthesizes the effects of resistance exercise on muscle-related outcomes in adult cancer populations, including skeletal muscle mass, performance and muscle-related biomarkers. METHODS: The systematic review protocol was developed in accordance with the Preferred Reporting…
Rank102.6
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Expert opinion on drug safety · 2026 · PMID 39960238
BACKGROUND: Cell-cycle protein-dependent kinase 4 and 6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) are widely used in patients with early and advanced breast cancer (BC). CDK4/6is also lead to numerous side effects. This study aims to elucidate the relationship between CDK4/6is and hepatotoxicities. RESEARCH DESIGN AND METHODS: As of 31 March 2024, we conducted a systematic search of PubMed, Embase, and the Cochrane Library databases, as well as several oncology conference proceedings. We incl…
Rank102.4
Different Acupuncture Combined With Three-Step Analgesic Therapy in the Treatment of Bone Metastatic Cancer Pain: A Network Meta-Analysis Based on Randomized Controlled Trials.
Pain research & management · 2026 · PMID 42684261
BACKGROUND: Cancer pain (CP) is predominantly caused by bone metastases, imposing a significant burden on both patients and society. The limitations of the three-step analgesic (TSA) therapy in managing CP have become increasingly evident. Although acupuncture demonstrates promising therapeutic effects for this condition, there is currently limited research comparing the efficacy of different acupuncture modalities. RESULTS: A total of 20 studies were included, involving 1640 patients. The tumor types included lung…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Safety And Adverse Effects250 records
Rank115.9
Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey.
Heart rhythm · 2026 · PMID 41342823
BACKGROUND: Cardiac electrophysiologists and electrophysiology (EP) laboratory professionals face underexplored occupational hazards, including direct and indirect effects of radiation exposure, orthopedic strain, and pregnancy-related concerns. Despite advances in radiation-reduction strategies, cumulative exposure continues to merit attention. OBJECTIVE: This study aimed to better understand these occupational risks. METHODS: A 20-question global (multiple-choice and open-ended) survey was distributed to Heart Rh…
Rank110.0
Preventing common shape deformities and complications in therapeutic mammoplasty: A practical guide.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026 · PMID 42413454
Therapeutic mammoplasty (TM) combines wide local excision with immediate volume displacement, enabling oncologically safe breast conservation while maintaining breast shape. Despite its benefits, postoperative complications and aesthetic deformities remain clinically relevant and may adversely affect patient satisfaction. Common sequelae include nipple-areola complex (NAC) malposition or necrosis, fat necrosis, bottoming-out, boxy breast contours, wound breakdown, and radiotherapy-associated fibrosis. This expert-o…
Rank107.9
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.
Cancer control : journal of the Moffitt Cancer Center · 2026 · PMID 42619658
IntroductionAntibody-drug conjugates (ADCs) are now widely used in breast cancer across multiple disease subtypes. With increasing clinical use, treatment-related toxicities have become an important factor in therapeutic decision-making. However, comparative safety data among ADCs are limited because direct head-to-head trials are lacking.MethodsWe conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials evaluating ADCs in breast cancer, with the literature search updated thr…
Rank107.5
Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
PloS one · 2024 · PMID 38781221
INTRODUCTION: As of 2020, breast cancer has emerged as the predominant cause of cancer incidence globally. Anthracycline-based chemotherapy serves as a crucial element in the treatment regimen for breast cancer. However, these anthracycline-based drugs are associated with cardiac toxicity. This study represents the first clinical quantitative analysis aimed at accurately determining the incidences of arrhythmia and abnormal electrocardiogram (ECG) changes, thereby providing valuable data to bolster clinical drug us…
Rank107.0
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Journal of integrative and complementary medicine · 2026 · PMID 42298832
INTRODUCTION: Patients with breast cancer commonly experience anxiety and sleep disturbance during and after treatment, and these symptoms are closely interrelated, negatively affecting the quality of life. Mindfulness-based interventions (MBIs) have been increasingly used as a nonpharmacological supportive approach. This systematic review and meta-analysis aimed to evaluate the effects of MBIs on anxiety and sleep quality in patients with breast cancer. METHODS: A systematic search of PubMed, Web of Science, Cochr…
Rank106.0
Effectiveness of Trolamine in Preventing Radiotherapy-Related Skin Toxicity in Breast Cancer: A Meta-Analysis and Trial Sequential Analysis Study of Randomized Controlled Trials.
Advances in skin & wound care · 2026 · PMID 42289089
OBJECTIVE: To evaluate the efficacy of trolamine in preventing radiotherapy-associated skin toxicity in patients with breast cancer. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Database, and Chinese Biomedical Literature Database (CBM). STUDY SELECTION: The included randomized controlled trials focused on the incidence of grade 0 to 1 cutaneous toxicity, the incidence of grade 2 cutaneous toxicity, the incidenc…
Rank105.4
Effect of exercise based prehabilitation on postoperative pain in breast cancer patients: a systematic review with meta-analysis.
Breast cancer (Tokyo, Japan) · 2026 · PMID 42530793
BACKGROUND: Postoperative pain is a common complication following breast cancer surgery, adversely influencing recovery and quality of life. Exercise-based prehabilitation, initiated before surgery to enhance physical readiness, has shown benefits in other surgical settings. However, its specific impact on postoperative pain in breast cancer patients remains unclear. METHODS: This systematic review and meta-analysis evaluated the effectiveness of exercise-based prehabilitation in reducing postoperative pain in wome…
Rank105.1
Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42690445
PURPOSE: Cancer therapy-related cardiac dysfunction (CTRCD) is a significant concern for breast cancer patients undergoing anthracycline-based chemotherapy. Although exercise has been proposed as a cardioprotective strategy, existing reviews have largely examined heterogeneous cancer populations receiving varied treatments, leaving a gap in the evidence base focused exclusively on anthracycline-induced CTRCD. This systematic review and meta-analysis aimed to address that gap by evaluating the effects of long-term e…
Rank104.5
Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.
Annals of medicine · 2026 · PMID 41949990
BACKGROUND: Despite the availability of several chemotherapeutic regimens for early-stage breast cancer (BC), the ideal combination and dosing strategy remain to be defined. Thus, we conducted a network meta-analysis (NMA) comparing the current chemotherapeutic regimens used in the treatment of women with early-stage BC. METHODS: We searched public database from inception to May 2021 for Phase II and Phase III trials of adjuvant chemotherapy in patients with early-stage BC following PRISMA guidelines. The primary e…
Rank104.2
Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 · PMID 41396594
IntroductionTaxane-induced peripheral neuropathy (TIPN) is a common toxicity among patients with breast cancer (BC). Numerous pairwise comparisons have been performed to evaluate neuropathy associated with different taxane agents (docetaxel, paclitaxel, cabazitaxel, nab-paclitaxel, liposomal paclitaxel, and paclitaxel injection concentrate for nanodispersion [PICN]). This network meta-analysis aimed to study the comparative incidence of TIPN associated with taxane agents in females with BC.MethodsA comprehensive da…
Rank102.6
Hepatic adverse events with CDK4/6 inhibitors: a systematic review combining meta-analysis and FAERS database.
Expert opinion on drug safety · 2026 · PMID 39960238
BACKGROUND: Cell-cycle protein-dependent kinase 4 and 6 inhibitors (CDK4/6is) in combination with endocrine therapy (ET) are widely used in patients with early and advanced breast cancer (BC). CDK4/6is also lead to numerous side effects. This study aims to elucidate the relationship between CDK4/6is and hepatotoxicities. RESEARCH DESIGN AND METHODS: As of 31 March 2024, we conducted a systematic search of PubMed, Embase, and the Cochrane Library databases, as well as several oncology conference proceedings. We incl…
Rank102.4
Different Acupuncture Combined With Three-Step Analgesic Therapy in the Treatment of Bone Metastatic Cancer Pain: A Network Meta-Analysis Based on Randomized Controlled Trials.
Pain research & management · 2026 · PMID 42684261
BACKGROUND: Cancer pain (CP) is predominantly caused by bone metastases, imposing a significant burden on both patients and society. The limitations of the three-step analgesic (TSA) therapy in managing CP have become increasingly evident. Although acupuncture demonstrates promising therapeutic effects for this condition, there is currently limited research comparing the efficacy of different acupuncture modalities. RESULTS: A total of 20 studies were included, involving 1640 patients. The tumor types included lung…
Rank101.4
Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42666138
OBJECTIVE: To systematically review the efficacy of chemotherapy combined with targeted therapy in the handling of advanced triple-negative breast cancer (TNBC). METHODS: A thorough literature search was carried out across several databases, including PubMed, EMBASE, ScienceDirect, and Chinese medical databases, for case-control trials on TNBC patients treated with chemotherapy combined with targeted therapy versus chemotherapy alone. Two separate researchers extracted the data, and the risk of bias was assessed us…
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.0
Ultra-Processed Food Consumption and Cancer Risk: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Journal of food science · 2026 · PMID 42619402
Evidence on the association between ultra-processed food (UPF) consumption and cancer risk is inconsistent, and systematic reviews (SRs) and meta-analyses (MAs) are fragmented across different cancer types and study populations. A comprehensive synthesis is needed to evaluate the robustness of the evidence. We therefore conducted an umbrella review (UR) of SRs and MAs to synthesize the available evidence on the association between UPF consumption and the risk of various cancers. PubMed, Embase, Web of Science, and …
Rank100.0
Relationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41808362
BACKGROUND: Menopausal hormone therapy (MHT) is widely prescribed for alleviating menopausal symptoms. Prior studies have mainly focused on individual hormone therapy formulations. This meta-analysis comprehensively synthesized evidence across various regimens to systematically evaluate the association between MHT and breast cancer risk. MATERIALS AND METHODS: We systematically searched CNKI, Wanfang, PubMed, and Web of Science from inception through August 2024. Eligible studies examining breast cancer risk follow…
Rank100.0
Association between adolescent alcohol consumption and cigarette smoking with adult risk of breast cancer: A systematic review and meta-analysis.
Preventive medicine · 2026 · PMID 42501871
OBJECTIVE: Alcohol and smoking are established carcinogens; however, evidence on adolescent exposure during mammary development on breast cancer risk remains inconsistent. This study assessed the associations between adolescent alcohol intake, smoking, and adult breast cancer risk. METHODS: A systematic search of PubMed/MEDLINE (1966), Web of Science (1900), and Scopus (1970) from inception to September 2025 identified 31 eligible studies (eleven on alcohol, twenty on smoking). Pooled relative risks (RRs) with 95% …
Rank100.0
Breast cancer incidence and mortality in population studies of radiation exposure: systematic review and meta-analysis.
British journal of cancer · 2026 · PMID 42303831
BACKGROUND: While breast cancer risk from high-dose ionising radiation is known, uncertainties remain about risks at lower doses and risk-modifying factors. We conducted a systematic review and meta-analysis of publications on radiation-associated risk of breast cancer in women. METHODS: We included studies published in 2005-2022 that assessed breast cancer incidence or mortality in women exposed to ionising radiation. Risk of bias was evaluated. Random-effects meta-analyses estimated excess relative risks per gray…
Rank100.0
CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates.
Frontiers in immunology · 2026 · PMID 42688140
UNLABELLED: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are established components of endocrine therapy for hormone receptor-positive (HR+), HER2-negative breast cancer. Beyond RB-dependent G1 arrest, these drugs alter antigen presentation, interferon signaling, checkpoint-ligand expression, suppressive immune-cell populations, and CD8+ T-cell fate. The direction and durability of these effects vary across tumors and treatment settings. Early combinations with immune checkpoint inhibitors (ICIs) have produc…
Rank100.0
Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42449201
OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in…
Rank100.0
Economic evaluations of neoadjuvant drug regimens in cancer: a systematic review.
Frontiers in public health · 2026 · PMID 42688252
BACKGROUND: Neoadjuvant drug therapy has become an important component of multidisciplinary cancer treatment, but newer targeted, immunotherapy-based, and multi-agent regimens are often associated with higher costs and uncertainty regarding long-term economic value. This systematic review evaluates the economic evidence for neoadjuvant drug regimens in cancer and summarizes key cost-effectiveness findings across tumor types and healthcare settings. METHODS: We systematically searched PubMed, Embase, and the Cochran…
Rank99.1
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.
International journal of cancer · 2026 · PMID 42056728
Chemotherapy-induced nausea and vomiting (CINV) remains an important side effect despite new antiemetic drugs. This study tried to understand the occurrence of CINV in patients receiving two different chemotherapy regimens. As part of the randomized controlled clinical trial SUCCESS C (NCT00847444), 1582 of the 3463 patients completed CINV diaries. Patients were randomized to receive either chemotherapy with FEC (5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel) or TC (docetaxel, cyclophosphamide)…
Rank97.8
French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
BMJ open · 2026 · PMID 42665344
INTRODUCTION: Symptoms associated with vulvovaginal atrophy affect up to 73% of patients with breast cancer, whether menopausal or non-menopausal, because certain breast cancer treatments are responsible for oestrogen deprivation on the genital tract. These symptoms are currently underdiagnosed and undertreated but can significantly impair the quality of life and can be a cause of premature discontinuation of adjuvant hormone therapy. Treatment of vulvovaginal atrophy in patients managed for breast cancer should be…
Rank97.6
Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.
Journal of the Egyptian National Cancer Institute · 2026 · PMID 42684555
BACKGROUND: Sentinel lymph node biopsy (SLNB) is standard for axillary staging in early breast cancer. While the combination of radioisotope and blue dye (e.g., patent blue V, PBV) remains the standard, it has limitations including logistics, variable identification rate (IR), and allergic potential. Indocyanine green (ICG) fluorescence is a promising alternative, but high-quality comparative evidence is needed. METHODS: This was a single-center, prospective, randomized controlled trial. Forty patients with early-s…
Rank97.0
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
The oncologist · 2026 · PMID 42496653
BACKGROUND: We report ophthalmological assessments, patient-reported visual symptoms/functioning, and characterization of visual effect AEs from the SERENA-6 study. MATERIALS AND METHODS: This double-blind, placebo-controlled phase III study included 315 patients with ER-positive advanced breast cancer receiving first-line aromatase inhibitor (AI)+CDK4/6 inhibitor (CDK4/6i). Patients with emerging ESR1 mutations in ctDNA and no radiological progression were randomized 1:1 to switch to camizestrant+CDK4/6i or contin…
Treatments That Failed Clinical Trials66 records
Rank100.5
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42508432
BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. M…
Rank100.3
Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.
BJS open · 2026 · PMID 42551036
BACKGROUND: Axillary lymph node dissection (ALND) in breast cancer causes substantial arm morbidity and long-term functional impairment. Less extensive axillary surgery, such as targeted axillary dissection (TAD), significantly reduces this risk. Although omission of ALND is standard in clinically node-negative disease with limited sentinel node involvement, this is not the case for patients with clinically node-positive disease undergoing upfront surgery. The aim of the SENOMAC-ULTRA trial is to evaluate whether T…
Rank99.6
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41937088
BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. PATIENTS AND METHODS: In the randomised, open-label, phase III TROPION-Breast02 trial, patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option were randomly assigned 1:1 to datopotamab deruxtecan (Dato-DXd; 6 mg/kg intravenously every 3…
Rank99.4
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
Journal of the National Cancer Institute · 2026 · PMID 41934626
BACKGROUND: Responses to anti-HER2 therapy can vary based on estrogen receptor expression and HER2 gene amplification. This study assessed the magnitude of benefit by adding pertuzumab to trastuzumab and chemotherapy by estrogen receptor and HER2 levels in the APHINITY trial. METHODS: APHINITY (ClinicalTrials.gov identifier NCT01358877; BIG 4-11) was a randomized, double-blind, phase 3 trial comparing pertuzumab with placebo added to adjuvant trastuzumab and chemotherapy in 4804 patients with HER2-positive early br…
Rank99.2
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.
The Lancet. Oncology · 2026 · PMID 42372743
BACKGROUND: Results from several studies, including our 15-year analysis, showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. Here, we present the scheduled 20-year analysis of the EORTC trial 22922/10925, evaluating the role of internal mammary and medial-supraclavicular (IM-MS) nodal irr…
Rank99.2
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
Nature medicine · 2026 · PMID 42350643
Patients with estrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathologic complete response (pCR) rates following neoadjuvant chemotherapy. Immune checkpoint inhibitors (ICIs) provide limited benefit in programmed death-ligand 1 (PD-L1)-negative tumors, characterized by an immune-cold tumor microenvironment. Here we hypothesized that immune-modulating stereotactic body radiation therapy (iSBRT; 3 × 8 Gy) could enhance response through tumor microenvironment reprogramming, and that …
Rank98.6
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.
ESMO open · 2026 · PMID 42275799
BACKGROUND: PADMA is a prospective, randomized, open-label, multicenter phase IV study comparing palbociclib and endocrine therapy (ET) with mono-chemotherapy (CT) +/- maintenance ET (at the discretion of the treating physician) as first-line therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (mBC). PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive first-line treatment with palbociclib + ET or i…
Rank98.4
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42613139
BACKGROUND: The phase 3 RxPONDER trial compared endocrine therapy (ET) alone or with chemotherapy (CET) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with recurrence score (RS) ≤25. CET benefit for the primary outcome, invasive disease-free survival (IDFS), was limited to premenopausal women who largely did not receive ovarian function suppression. In this study, we assessed hormones associated with ovarian reserve to further refine the prediction of CET …
Rank98.2
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42364416
BACKGROUND: Dose-dense (DD) adjuvant chemotherapy represents a standard treatment for patients with high-risk node-positive early-stage HER2-negative breast cancer (BC). In this exploratory analysis of the GIM2 trial, we investigated the efficacy of DD chemotherapy among patients with HER2-negative BC according to HER2 immunohistochemistry (IHC) score. METHODS: Patients with node-positive early BC were randomized to receive either DD or standard schedule anthracycline- and taxane-based chemotherapy. HER2 status was…
Rank98.0
Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival.
Acta anaesthesiologica Scandinavica · 2026 · PMID 42210709
INTRODUCTION: This study investigates long-term survival in the Cancer and Anaesthesia (CAN) study, focusing on the potential impact of local anaesthetic infiltration during breast cancer surgery. A positive effect from peritumoral infiltration has recently been suggested. We conducted an exploratory data analysis to examine a possible association between uncontrolled exposure to local anaesthetics during breast cancer surgery and long-term survival. METHODS: Breast cancer patients were recruited to compare long-te…
Rank97.6
Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.
Journal of the Egyptian National Cancer Institute · 2026 · PMID 42684555
BACKGROUND: Sentinel lymph node biopsy (SLNB) is standard for axillary staging in early breast cancer. While the combination of radioisotope and blue dye (e.g., patent blue V, PBV) remains the standard, it has limitations including logistics, variable identification rate (IR), and allergic potential. Indocyanine green (ICG) fluorescence is a promising alternative, but high-quality comparative evidence is needed. METHODS: This was a single-center, prospective, randomized controlled trial. Forty patients with early-s…
Rank97.4
The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial.
BMC medicine · 2026 · PMID 42557562
BACKGROUND: The tumour microenvironment (TME) influences breast cancer progression and treatment response. We investigated whether TME composition predicts tamoxifen benefit in postmenopausal women with oestrogen receptor-positive, HER2-negative (ER+HER2-) breast cancer. METHODS: This study included 513 patients from the Stockholm Tamoxifen (STO-3) trial, which randomised postmenopausal, lymph node-negative women to tamoxifen or no endocrine therapy. Bulk tumour transcriptomes were deconvoluted with the ConsensusTM…
Rank97.3
Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42067068
PURPOSE/OBJECTIVE: The FAST-Forward randomised nodal sub-study primary analysis showed non-inferiority for 5-year patient-reported arm/hand swelling following adjuvant breast/chest wall and axillary radiotherapy given in 26 Gy in 5 fractions (Fr) over 1 week compared to 40 Gy in 15Fr over 3 weeks. This subsequent analysis investigates the association between patient, tumour and treatment factors and development of long-term arm/hand swelling. MATERIAL/METHODS: Data from 469 patients randomised to adjuvant radiother…
Rank97.1
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42372741
BACKGROUND: Patients with stage III, human epidermal-growth-factor-receptor 2 (HER2; also known as ERBB2)-negative breast cancer with homologous recombination deficiency (HRD) had a 4-year overall survival of 35% after anthracycline-based chemotherapy versus 78% after intensified alkylating chemotherapy with autologous stem cell rescue (IACT) in a post-hoc analysis of an earlier randomised controlled trial. In this study, we aimed to prospectively assess 4-year overall survival with IACT and establish whether this …
Rank97.0
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42308863
BACKGROUND: Phosphoinositide 3-kinase (PI3K) pathway, involved in obesity-related signalling, may influence efficacy and toxicity of PI3K inhibitors (PI3Ki). We explored associations between body mass index (BMI) and objective response rate (ORR), safety, molecular features, and breast density in the LORELEI trial. METHODS: LORELEI (NCT02273973) was a randomized trial evaluating neoadjuvant PI3Ki taselisib plus letrozole vs placebo plus letrozole in patients with estrogen receptor-positive/HER2-negative early breas…
Rank96.9
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42162664
BACKGROUND: Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. PATIENTS AND METHODS: In the randomized phase III NeoTRIPaPDL1 trial, 280 patients with high-risk TNBC received neoadjuvant carboplatin plus nab-paclitaxel (CT, n = 142) or the same regimen with atezolizumab (CT/A, n = 138). Tumor biopsies were collected …
Rank96.6
Impact of Timing and Format of Patient Decision Aids on Involvement in Shared Decision-Making for Patients With Breast Cancer: The IMPACTT Randomized, Controlled Study.
Clinical breast cancer · 2026 · PMID 42531657
BACKGROUND: For people with breast cancer facing adjuvant treatment decisions, it is unclear whether providing a patient decision aid (PtDA) before versus during the consultation leads to greater involvement in shared decision-making (SDM). The overall aim was to evaluate the effect of a digital preconsult PtDA compared with an identical in-consult paper-based PtDA. PATIENTS AND METHODS: In this randomized controlled trial, patients with breast cancer eligible for adjuvant treatment were randomized to a digital PtD…
Rank96.5
Efficacy of Ketamine for Opioid-Free Anesthesia (OFA) in Patients Undergoing Mastectomy: A Randomized Controlled Trial.
Asian journal of anesthesiology · 2025 · PMID 42509583
BACKGROUND: Opioid-free anesthesia (OFA) is an emerging practice in cancer care, providing adequate analgesia with reduced side effects. The objective of the study is to evaluate whether ketamine can replace morphine for performing OFA by assessing the acute pain relief achieved and to evaluate its effect on chronic pain. METHODS: A total of 182 women undergoing modified radical mastectomy were recruited and randomized into the morphine group and the ketamine group. Participants in the morphine group received 0.05 …
Rank95.8
Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.
Cancer biotherapy & radiopharmaceuticals · 2026 · PMID 41645929
OBJECTIVE: To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy. METHODS: A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, n = 40) or the observation group (OG, n…
Rank95.7
Investigating the effect of web-based education on positive mental health of family caregivers of breast cancer patients: a quasi-experimental study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42542461
BACKGROUND AND AIM: The increasing incidence of cancer and the fact that the family is an important factor in cancer care; attention to the positive mental health of cancer patients should be sought to provide solutions to improve the mental health of these caregivers. The present study aimed to investigate the effect of web-based education on positive mental health of family caregivers of breast cancer patients undergoing chemotherapy in educational and treatment centers of Zahedan University of Medical Sciences. …
Rank95.5
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
Nature communications · 2026 · PMID 42649154
Pre-clinical evidence suggests that stereotactic ablative body radiotherapy (SABR) can enhance systemic anti-tumor responses when combined with immune checkpoint inhibition, although optimal fractionation remains uncertain. Here we conducted a phase II multi-center randomized trial (AZTEC trial; ClinicalTrials.gov identifier NCT03464942) to investigate the efficacy and safety of single-fraction (SF: 20 Gy; n = 27) or multi-fraction (MF: 24 Gy in three fractions; n = 27) SABR followed by anti-PD-L1 atezolizumab in 5…
Rank95.5
The MEC90 of Ropivacaine for Ultrasound-Guided Pectoral Nerve Block Type II for Modified Radical Mastectomy: A Biased-Coin Up-and-Down Sequential Trial.
Drug design, development and therapy · 2026 · PMID 42491688
PURPOSE: This study aimed to determine the 90% minimum effective concentration (MEC90) of a fixed volume of 30 mL ropivacaine for ultrasound-guided pectoral nerve block type II (PECS IIblock) in patients undergoing modified radical mastectomy (MRM), using a biased-coin design up-and-down sequential method (BCD-UDM). METHODS: Patients were enrolled sequentially according to the BCD-UDM protocol. All patients received 30 mL of ropivacaine for ultrasound-guided PECS II block. The initial ropivacaine concentration was …
Rank95.4
Mat Pilates vs. belly dance: Effects on cardiorespiratory fitness and body composition in women with breast cancer: A randomized trial.
Maturitas · 2026 · PMID 42296761
OBJECTIVE: To examine the effects of 16 weeks of Mat Pilates or belly dance, compared with a control condition, on cardiorespiratory fitness and body composition in women with breast cancer undergoing hormone therapy, with follow-up at 6 and 12 months. METHODS: In this randomized clinical trial, 52 women were allocated to Mat Pilates (n = 18), belly dance (n = 18), or control (n = 16) groups. Exercise groups trained three times per week for 60 min over 16 weeks. The control group maintained usual activities and att…
Rank95.2
The effects of a financial navigation intervention on financial toxicity among patients with breast cancer in China: A randomized controlled trial.
Breast (Edinburgh, Scotland) · 2026 · PMID 42224905
BACKGROUND: Financial toxicity (FT) is a common issue faced by breast cancer patients worldwide. Although financial navigation (FN) is a promising approach to alleviate FT, its effectiveness in China's context remains underexplored. OBJECTIVES: To evaluate the effects of a FN intervention on FT, cost-related health literacy (CRHL), shared decision-making (SDM) ability, and perceived stress of patients with breast cancer. METHODS: This was a cluster randomized controlled trial. Participants were randomized to the FN…
Rank95.2
Evaluation of the protective effect of chamomile oral solution on the incidence of neurotoxicity caused by paclitaxel in breast cancer patients.
Anti-cancer drugs · 2026 · PMID 41538720
Neurotoxicity is one of the major complications in cancer patients following paclitaxel-containing regimens. Matricaria chamomilla L., isolated from the German chamomile, has anti-inflammatory and antioxidant features. In this study we evaluated the preventive impact of a chamomile oral formulation against paclitaxel-induced neurotoxicity in cancer patients. In this triple-blind clinical trial, cancer patients on paclitaxel were randomly allocated to chamomile oral solution ( n = 40), or the placebo ( n = 40) 5 ml …
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.